AGREEMENT AND PLAN OF MERGER
AGREEMENT
AND PLAN OF MERGER
THIS
AGREEMENT AND PLAN OF MERGER (the “Agreement”)
is
entered into as of November 16, 2006, by and among Neuro-Hitech,
Inc., f/k/a Neuro-Hitech Pharmaceuticals, Inc.,
a
Delaware corporation (“Buyer”),
QA
Acquisition Corp., a Delaware corporation (“Buyer
Sub”),
QA
Merger LLC, a Delaware limited liability company (“Buyer
LLC”),
Q-RNA, Inc., a Delaware corporation (“Company”)
and
Xx. Xxxxx Xxxxxxxx, as the proposed “Representative”
of
the
Company security holders listed hereto on Exhibit
A
(the
“Company
Securityholders”).
RECITALS
A. The
parties intend that, subject to the terms and conditions of this Agreement,
Company will engage in a business combination with Buyer pursuant to a two-step
process as follows (together, the “Merger”): (i) first, Buyer Sub will merge
with and into the Company, with the Company being the surviving corporation
of
such merger (“Merger 1”), and (ii) promptly after the consummation of Merger 1,
the Company will merge with and into Buyer LLC, with Buyer LLC being the
surviving entity in such merger (“Merger 2”); all pursuant to the terms and
conditions of this Agreement and the applicable provisions of the Delaware
General Corporation Law and the Delaware Limited Liability Company Act (as
appropriate, “Delaware Law”). Upon the effectiveness of Merger 1, (x) all the
outstanding capital stock of Company (“Company Stock”) will be converted into
common stock of Buyer (“Buyer Stock”) and warrants to purchase Buyer Common
Stock (“Buyer Warrants”), (y) Buyer will assume all outstanding options and
warrants to purchase shares of common stock of Company, as provided in this
Agreement, and (z) all of the issued and outstanding capital stock of Buyer
Sub
will be converted into an equal number of shares of the Company’s common stock
(the “New Company Stock”). Upon the effectiveness of Merger 2, all of the New
Company Stock shall be cancelled and of no further force or effect.
B. The
Merger is intended to be treated as a “reorganization” pursuant to the
provisions of Section 368(a)(1)(A) of the Internal Revenue Code of 1986, as
amended (the “Code”).
As an
additional part of the plan of reorganization, the Company’s Convertible
Debentures shall be exchanged for Buyer Common Stock and Buyer
Warrants.
C. The
board
of directors of Company (i) has determined that the Merger is advisable and
in
the best interests of Company and its stockholders, (ii) has approved this
Agreement, the Merger and the other transactions contemplated by this Agreement
and (iii) has determined to recommend that the Company stockholders adopt and
approve this Agreement and approve the Merger.
In
consideration of the foregoing and the representations, warranties, covenants
and agreements set forth in this Agreement, the parties agree as
follows:
1.
|
THE
MERGER
|
1.1 The
Merger.
At
the
Effective Time (as defined in Section 1.2.1), and subject to and upon the terms
and conditions of this Agreement and the applicable provisions of Delaware
Law,
Buyer
Sub shall be merged with and into the Company, the separate corporate existence
of Buyer Sub shall cease, and the Company shall continue as the surviving
corporation. Promptly after the effectiveness of Merger 1 but no later than
one
business day after the consummation of Merger 1, the Company shall be merged
with and into Buyer LLC, the separate existence of the Company shall cease,
and
Buyer LLC shall continue as the surviving entity. The Buyer LLC as the ultimate
surviving entity after the Merger is hereinafter sometimes referred to as the
“Surviving Entity” and will be governed by the laws of the State of
Delaware.
1
1.2 Effective
Time; Closing.
1.2.1 Subject
to the provisions of this Agreement, the parties hereto shall cause Merger
1 to
be consummated by filing a Certificate of Merger (“Certificate
of Merger 1”)
with
the Secretary of State of Delaware in accordance with the relevant provisions
of
Delaware Law (the time of such filing with the Secretary of State of Delaware
or
such later time as may be agreed in writing by the Company and Buyer and
specified in Certificate of Merger 1, the “Effective
Time”)
as
soon as practicable on or after the Closing Date (as defined in Section
1.2.2).
Subject to the provisions of this Agreement, the Buyer shall cause Merger 2
to
be consummated by filing a Certificate of Merger (“Certificate
of Merger 2”
and
together with Certificate of Merger 1, the “Certificates
of Merger”)
with
the Secretary of State of Delaware in accordance with the relevant provisions
of
Delaware Law as soon as practicable on or after the Effective Time, but
effective no later than the one business day after the effective date of Merger
1.
1.2.2 Subject
to the earlier termination of this Agreement in Section 8
below,
the
transactions contemplated hereby shall be consummated by the exchange of
documents and instruments (“Closing”)
by
mail, courier or telecopy
promptly
following the satisfaction or waiver of all conditions to closing (the
“Closing
Date”).
Concurrently with the Closing, Certificate of Merger 1 and Certificate of Merger
2 will be filed in the office of the Delaware Secretary of State.
1.3 Charter
Documents.
1.3.1 Certificates
of Incorporation and Formation.
At the
Effective Time following Merger 1, the certificate of incorporation of the
Company, as in effect immediately prior to the Effective Time, shall remain
in
effect. Upon the effectiveness of Merger 2, the certificate of formation of
Buyer LLC shall be the certificate of formation of the Surviving Entity,
provided however,
that
the certificate of formation of the Surviving Entity will be amended to reflect
that the name of the Surviving Corporation shall be “Q-RNA, LLC”.
1.3.2 Bylaws
and Operating Agreement.
At the
Effective Time following Merger 1, the bylaws of the Company, as in effect
immediately prior to the Effective Time, shall remain in effect. Upon the
effectiveness of Merger 2, the operating agreement of Buyer LLC shall be the
operating agreement of the Surviving Entity, provided however, that the
operating agreement of the Surviving Entity will be amended to reflect that
the
name of the Surviving Corporation shall be “Q-RNA, LLC”
2
1.4 Board
of Directors and Officers.
The
directors and corporate officers of the Company immediately prior to the
Effective Time shall continue to be the directors and corporate officers of
the
Company until the effectiveness of Merger 2, at which time they all shall
resign. The managers of Buyer LLC immediately prior to the effectiveness of
Merger 2 shall continue to be the managers of the Surviving Entity, each to
hold
office in accordance with the certificate of formation and operating agreement
of the Surviving Entity, until their respective successors are duly elected
or
appointed (as the case may be) and qualified.
1.5 Effect
on Capital Stock.
By
virtue of the Merger 1 and Merger 2, and without any action on the part of
Buyer, Buyer Sub, Buyer LLC or the Company:
1.5.1 At
the
Effective Time, each share of Company Common Stock and Company Preferred Stock
validly issued and outstanding prior to the Effective Time shall be changed
and
converted into the number of shares of Buyer Common Stock and Buyer Warrants
set
forth on Exhibit
B.
(The
total number of shares of Buyer Common Stock and Buyer Warrants issued pursuant
to this Section 1.5.1,
Section
1.6
and
Section 1.10 shall be referred to herein as the “Merger
Consideration”).
The
Buyer Warrants shall be certificated in a form that is mutually acceptable
to
Buyer and the Company.
1.5.2 At
the
Effective Time, any share of Company Common Stock or Company Preferred Stock
held in the treasury of the Company immediately prior to the Effective Time
shall, by virtue of Merger 1, be canceled and retired and cease to exist as
of
the Effective Time and no consideration shall be paid with respect
thereto.
1.5.3 At
the
Effective Time, each share of Buyer Sub capital stock outstanding immediately
prior to the Effective Time will be changed and converted into an identical
outstanding share of New Company Stock.
1.5.4 Upon
the
effectiveness of Merger 2, (i) each share of New Company Stock shall, by virtue
of Merger 2, be canceled and retired and cease to exist and no consideration
shall be paid with respect thereto, and (ii) each membership interest in Buyer
LLC outstanding immediately prior to the effectiveness of Merger 2 will continue
to remain issued and outstanding.
1.6 Convertible
Debentures.
At the
Effective Time, the principal amount of the then outstanding Company convertible
notes and accrued interest due thereunder (the “Convertible
Debentures”)
payable to the individuals or entities listed on Exhibit
B
shall be
canceled and exchanged for the number of shares of Buyer Common Stock and Buyer
Warrants set forth opposite such individuals or entities’ names on Exhibit
B.
1.7 Dissenting
Shares.
Holders
of shares of Company Stock who have complied with all requirements for
perfecting stockholders’ rights of appraisal, as set forth in Section 262 of the
Delaware Law, shall be entitled to their rights under Delaware Law with respect
to such shares (“Dissenting
Shares”).
3
1.8 No
Fractional Shares.
No
fractional shares of Buyer Common Stock or Buyer Warrants will be issued in
connection with the Merger, but in lieu thereof each holder of Company Stock
or
Convertible Debentures who would otherwise be entitled to receive a fraction
of
a share of Buyer Common Stock or Buyer Warrants will receive from Buyer,
promptly after the Effective Time, a number of shares of Buyer Common Stock
or
Buyer Warrants rounded up or down to the nearest whole number.
1.9 Exchange
of Certificates.
1.9.1 Exchange
Agent.
Buyer
shall act as exchange agent (the “Exchange
Agent”)
in the
Merger. Prior to the Closing Date, Buyer shall obtain from Empire Stock Transfer
Inc., Buyer’s transfer agent, certificates representing the shares of Buyer
Common Stock issuable to the Company Securityholders pursuant to this
Agreement.
1.9.2 Exchange
Procedures.
At the
Closing upon surrender, as appropriate, of (i) certificates representing shares
of Company Stock, (ii) original agreements representing warrants to acquire
Company Stock, and (iii) original instruments evidencing Convertible Debentures
(as applicable for each Company Securityholder, “Company
Securities”),
in
each case for cancellation to the Buyer, together with a duly executed
counterpart signature page to the Stakeholder Agreement (as defined in Section
1.14 below), the holder of such Company Securities shall be entitled to receive
in exchange therefor, and subject to Section 9.9 below, Buyer shall issue and
deliver to such holder or the Representative for further distribution to such
holder, one or more certificates representing that number of whole shares of
Buyer Common Stock and the Buyer Warrants set forth opposite such Company
Securityholders’ name on Exhibit
B,
and the
Company Securities so surrendered shall forthwith be canceled. Until surrendered
as contemplated by this Section 1.9,
each
Company Security shall be deemed, on and after the Effective Time, to evidence
the ownership of the number of Buyer Warrants and full shares of Buyer Common
Stock into which such Company Securities shall have been so
converted.
1.9.3 Distributions
with Respect to Unsurrendered Certificates.
No
dividends or other distributions declared or made after the Effective Time
with
respect to Buyer Common Stock with a record date after the Effective Time shall
be paid to the holder of any unsurrendered Company Securities with respect
to
Buyer Common Stock represented thereby, until the holder of record of such
Certificate shall surrender such Company Securities. Subject to the effect
of
applicable laws, following surrender of any such Company Securities, there
shall
be paid to the record holder of the certificates representing whole shares
of
Buyer Common Stock issued in exchange therefor, without interest, (i) the amount
of dividends or other distributions with a record date after the Effective
Time
theretofore paid with respect to such whole shares of Buyer Common Stock, and
(ii) at the appropriate payment date, the amount of dividends or other
distributions with a record date after the Effective Time but prior to surrender
and a payment date subsequent to surrender payable with respect to such whole
shares of Buyer Common Stock.
1.9.4 No
Further Ownership Rights in Company Securities.
All
Buyer Warrants and shares of Buyer Common Stock issued upon the surrender for
exchange of such Company Securities in accordance with the terms of this
Agreement (including any cash paid pursuant to Section 1.9.3)
shall
be deemed to have been issued in full satisfaction of all rights pertaining
to
such Company Securities. After the Effective Time there shall be no further
registration of transfers on the stock transfer books of the Surviving Entity
or
Company of the Company Securities which were outstanding immediately prior
to
the Effective Time. If, after the Effective Time, Company Securities are
presented to the Surviving Entity or Buyer for any reason, they shall be
canceled and exchanged as provided in this Section 1.9.
4
1.9.5 No
Liability.
Neither
Buyer nor Company shall be liable to any holder of shares of Company Securities
for any amount properly delivered to a public official pursuant to any
applicable abandoned property, escheat or similar law.
1.9.6 Lost,
Stolen or Destroyed Certificates.
In the
event any Company Securities shall have been lost, stolen or destroyed, the
Buyer shall issue in exchange for such lost, stolen or destroyed Company
Securities, upon the making of an affidavit of that fact by the holder thereof,
such Buyer Warrants, shares of Buyer Common Stock, and any dividends or
distributions payable pursuant to this Section 1.9.
1.10 Assumption
of Options and Warrants.
Promptly after the Effective Time, Buyer will notify in writing each holder
of a
Company Option or Company Warrant of the assumption of such Company Option
or
Warrant by Buyer, and the number of shares of Buyer Common Stock that are then
subject to such option and the exercise price of such option, as determined
pursuant to Section 1.11
hereof.
“Company
Option”
means
any option or right granted, and not exercised or expired, to a current or
former employee, director or independent contractor of the Company or any
predecessor thereof to purchase Company Common Stock pursuant to any stock
option, stock bonus, stock award or stock purchase plan, program or arrangement
of the Company or any predecessor thereof or any other contract or agreement
entered into by the Company. “Company
Warrant”
means
any warrant, exchangeable or convertible securities or other rights or
agreements to purchase or otherwise acquire any Company Common Stock other
than
the Company Options, the Company Preferred Stock and the Convertible
Debentures.
1.11 Company
Options and Company Warrants.
1.11.1 Options.
At the
Effective Time, each holder of an outstanding Company Option to purchase Company
Common Stock granted: (i) under Company’s 2002 Stock Incentive Plan, as amended
(the “Company
Stock Plan”),
and
(ii) to Xx. Xxxxxx X. Xxxxxx pursuant to that certain Option Agreement dated
as
of July 18, 2005 (“Xxxxxx
Option”),
shall
be entitled, in accordance with the terms of such option, to purchase after
the
Effective Time that number of shares of Buyer Common Stock set forth opposite
such option holder’s name in the column entitled “Number of NHI Options” on page
2 of Exhibit
B
(“Buyer
Options”),
and
the exercise price per share for each such Option will be equal to the exercise
price set
forth
opposite such option holder’s name in the column entitled “NHI Exercise Price”
on page 2 of Exhibit
B.
All
Buyer Options shall be fully vested and exercisable immediately after the
Effective Time. The other terms of the Company Options will be unchanged;
provided, that within 12 months following the Closing, Buyer shall seek the
approval of Buyer’s stockholders for the treatment of the Buyer Options as
“incentive stock option” under Section 422 of the Code, and if Buyer’s
stockholders shall not so approve, the Buyer Options shall be non-qualified
stock options, to the extent required by law. For
the
avoidance of doubt, notwithstanding the right of Company Securityholders to
receive Buyer Warrants at the Closing as part of the Merger Consideration,
no
Buyer Warrants will be issued upon the exercise of any Company Option after
the
Effective Time.
5
1.11.2 Warrants.
At the
Effective Time, each outstanding warrant to purchase shares of Company Common
Stock (each a “Company
Warrant”),
whether or not exercisable, will be assumed by Buyer. Each Company Warrant
so
assumed by Buyer under this Agreement will continue to have, and be subject
to,
the same terms and conditions set forth in the applicable Company Warrant
immediately prior to the Effective Time (including, without limitation, any
vesting provisions), except that (i) each Company Warrant will be exercisable
(or will become exercisable in accordance with its terms) for that number of
whole shares of Buyer Common Stock set forth opposite such warrant holder’s name
on Exhibit
B
and (ii)
the per share exercise price for the shares of Buyer Common Stock issuable
upon
exercise of such assumed Company Warrant will be equal to the exercise price
of
the Buyer Warrants. For the avoidance of doubt, notwithstanding the right of
Company Securityholders to receive Buyer Warrants at the Closing as part of
the
Merger Consideration, no Buyer Warrants will be issued upon the exercise of
any
Company Warrant after the Effective Time.
1.12 Reallocation
of Merger Consideration.
It is
expressly acknowledged that, as a result of the exercise and/or cancellation
of
Company Options and Company Warrants, as well as internal negotiations among
the
Company Securityholders, it may be necessary for Exhibit
B
to be
amended following the date of this Agreement. The Company shall be entitled,
from time to time (but not more than 2 days prior to the Closing), to submit
to
Buyer a revised version of Exhibit
B
reallocating the Merger Consideration among the Company Securityholders,
provided that any such revised Exhibit
B
shall
not result in the Buyer issuing more Merger Consideration than is set forth
on
the original Exhibit
B
attached
to this Agreement.
1.13 Further
Assurances.
Company
agrees that if, at any time before or after the Effective Time, Buyer considers
or is advised that any further deeds, assignments or assurances are reasonably
necessary or desirable to vest, perfect or confirm in Buyer title to any
property or rights of Company, Buyer and its proper officers and directors
may
execute and deliver all such proper deeds, assignments and assurances and do
all
other things necessary or desirable to vest, perfect or confirm title to such
property or rights in Buyer and otherwise to carry out the purpose of this
Agreement, in the name of Company or otherwise.
1.14 Appointment
of Representative; Agreements Binding on Company
Securityholders.
The (a)
holders of Convertible Debentures, Company Warrants and Company Options through
the execution of an Omnibus Stakeholder Agreement attached hereto as
Exhibit
C
(“Stakeholder
Agreement”)
will
have, and (b) the Company stockholders by virtue of having approved and adopted
this Agreement under Delaware Law will, as a specific term of the Merger, will
be deemed to have (i) irrevocably constituted and appointed, effective as of
the
Effective Time, Xx. Xxxxx Xxxxxxxx (together with his/her/its permitted
successors, the “Representative”),
as
their true and lawful agent, proxy and attorney-in-fact, to exercise all or
any
of the powers, authority and discretion conferred on him or her under this
Agreement, or any letter of transmittal delivered in accordance with the
provisions of Section 1.9
hereof
and (ii) irrevocably agreed to, and be bound by and comply with, all of the
obligations of the Company Securityholders set forth in Section 9
with
respect to the indemnification of the Buyer. The Representative agrees to act
as, and to undertake the duties and responsibilities of, such agent and
attorney-in-fact. This power of attorney is coupled with an interest and is
irrevocable.
6
1.15 Securities
Law Issues.
1.15.1 Based
in
part on the representations of the Company Securityholders made in the
“accredited investor” questionnaires described in Section 7.15,
the
Buyer Common Stock and Buyer Warrants to be issued in the Merger will be issued
pursuant to an exemption from registration under Section 4(2) of the Securities
Act of 1933, as amended (the “Securities
Act”)
and/or
Rule 506 under Regulation D promulgated under the Securities Act and applicable
state securities laws.
1.15.2 The
shares of Buyer Common Stock and Buyer Common Stock issuable upon exercise
of
the Buyer Warrants will not have been registered and will be deemed to be
“restricted securities” under federal securities laws and may not be resold
without registration under or exemption from the Securities Act. Each
certificate evidencing shares of Buyer Common Stock and Buyer Common Stock
issuable upon exercise of the Buyer Warrants will bear the following
legend:
THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION WITHOUT EXEMPTION UNDER THE
SECURITIES ACT OR AN OPINION OF LEGAL COUNSEL REASONABLY ACCEPTABLE TO
NEURO-HITECH, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.
Any
certificates issued as evidence for the Buyer Warrants shall bear a similar
legend.
1.16 Tax
Free Reorganization.
The
parties intend to adopt this Agreement as a “plan of reorganization” and shall
treat the effect of Merger 1 and Merger 2 for purposes of the Code as if the
Company merged with and into Buyer in accordance with the provisions of Section
368(a)(1)(A) of the Code and analogous state law. The parties believe that
the
value of the Merger Consideration to be received in Merger 1 is approximately
equal to the value of (i) the Company Stock to be surrendered in exchange
therefor, and (ii) the Company Options to be assumed by the Buyer pursuant
to
Section 1.11.1 above. The Buyer Stock and Buyer Warrants issued in the Merger
will be issued solely in exchange for the Company Stock and assumption of
Company Options, and no other transaction other than the Merger represents,
provides for or is intended to be an adjustment to, the consideration paid
for
the Company Stock. Except for the Buyer Warrants and cash paid for Dissenting
Shares, no consideration that could constitute “other property” within the
meaning of Section 356 of the Code is being paid by Buyer for the Company Stock
in the Merger, other than possibly items described in Section 10.7. The parties
intend and shall treat the Spinoff (as hereinafter described) as a distribution
to the Company Securityholders that qualifies under Section 355(a)(1)(A) of
the
Code and any analogous state provision. The parties shall not take any position
on any tax returns inconsistent with this Section 1.16 and will not take, nor
fail to take, any action, which action or failure would jeopardize the
qualification of the Merger as a “reorganization” within the meaning of Section
368(a)(1)(A) of the Code or the qualification of Spinoff as a distribution
under
Section 355(a)(1)(A), provided that neither Buyer nor Buyer Sub shall thereby
be
required to alter the Merger Consideration. The provisions and representations
contained or referred to in this Section 1.16 shall survive until the expiration
of the applicable statute of limitations.
7
2.
|
REPRESENTATIONS
AND WARRANTIES OF
COMPANY
|
Except
as
set forth on the Company Disclosure Letter (the “Company
Disclosure Schedule”)
delivered to Buyer and Buyer Sub herewith, Company hereby represents and
warrants to Buyer and Buyer Sub as set forth in this Section 2. The Company
Disclosure Schedule shall be arranged in Sections and Subsections corresponding
to the numbered Sections and Subsections contained in this Section 2. The
disclosures in any Section of the Disclosure Schedule shall qualify (i)
the
corresponding Subsection in
this
Section
2,
and
(ii)
other
Subsections in this Section 2 to the extent it is reasonable
from a
reading of the disclosure (notwithstanding the absence of a specific cross
reference) that such disclosure is applicable to such other Subsections.
2.1 Organization
and Good Standing.
Company
is a corporation duly organized, validly existing and in good standing under
the
laws of the state of its incorporation, has the corporate power and authority
to
own, operate and lease its properties and to carry on its business as now
conducted and as proposed to be conducted, and is qualified as a foreign
corporation in each jurisdiction listed on Section 2.1
of the
Company Disclosure Schedule. Except as listed on Section 2.1
of the
Company Disclosure Schedule, Company does not own or lease any real property,
has no employees and does not maintain a place of business in any foreign
country or in any state of the United States other than New York.
2.2 Power,
Authorization and Validity.
2.2.1 Power
and Capacity.
Company
has the right, power, legal capacity and authority to enter into and, subject
to
receipt of appropriate approvals from the holders of Company Stock, perform
its
obligations under this Agreement, and all agreements to which Company is or
will
be a party that are required to be executed pursuant to this Agreement (the
“Company
Ancillary Agreements”).
The
execution, delivery and performance of this Agreement and the Company Ancillary
Agreements have been duly and validly approved and authorized by Company’s board
of directors as required by applicable law and Company’s certificate of
incorporation and bylaws.
2.2.2 No
Filings.
No
filing, authorization or approval, governmental or otherwise, is necessary
to
enable Company to enter into, and to perform its obligations under, this
Agreement and the Company Ancillary Agreements, except for (a) the filing of
the
Certificates of Merger with the Delaware Secretary of State, and the filing
of
appropriate documents with the relevant authorities of other states in which
Company is qualified to do business, if any, (b) such filings as may be required
to comply with federal and state securities laws, (c) the approval of the
Company stockholders of the transactions contemplated hereby, (d) consent of
all
of the holders of Convertible Debentures, (e) consent of the holders of Company
Options and Company Warrants, (e) consents required under contracts disclosed
in
Section 2.6
of the
Company Disclosure Schedule as exceptions to the representation made in the
last
sentence of Section 2.6
below.
8
2.2.3 Binding
Obligation.
Subject
to approval of this Agreement and the Merger by the Company stockholders, this
Agreement and the Company Ancillary Agreements are, or when executed by Company
will be, valid and binding obligations of Company enforceable in accordance
with
their respective terms, except as to the effect, if any, of (a) applicable
bankruptcy and other similar laws affecting the rights of creditors generally,
(b) rules of law governing specific performance, injunctive relief and other
equitable remedies and (c) the enforceability of provisions requiring
indemnification in connection with the offering, issuance or sale of securities;
provided, however, that the Certificates of Merger will not be effective until
filed with the Delaware Secretary of State.
2.3 Capitalization.
2.3.1 Authorized
and Outstanding Capital Stock.
The
authorized capital stock of Company consists of 7,840,000 shares of Common
Stock, $0.001 par value per share, of which 3,552,866 shares are issued and
outstanding and 2,462,000 shares of convertible Preferred Stock, $0.001 par
value
per share,
of
which 2,441,718 shares are issued and outstanding. Each of the Company
stockholders holds good and marketable title to such Company shares, free and
clear of all liens, agreements, voting trusts, proxies and other arrangements
or
restrictions of any kind whatsoever (other
than normal restrictions on transfer under applicable federal and state
securities laws and as set forth in the Company’s Amended and Restated
Stockholders Agreement dated as of December 13, 2002, which shall be terminated
on or prior to the Closing Date).
All
issued and outstanding shares of Company Common Stock and Preferred Stock have
been duly authorized and were validly issued, are fully paid and nonassessable,
are not subject to any right of rescission, are not subject to preemptive rights
by statute, the certificate of incorporation or bylaws of Company, or any
agreement or document to which Company is a party or by which it is bound and
have been offered, issued, sold and delivered by Company in compliance with
all
registration or qualification requirements (or applicable exemptions therefrom)
of applicable federal and state securities laws. Company is not under any
obligation to register under the Securities Act any of its presently outstanding
securities or any securities that may be subsequently issued, except pursuant
to
that certain Amended and Restated Registration Rights Agreement dated as of
December 13, 2002, which shall be terminated on or prior to the Closing Date.
There
is
no liability for dividends accrued but unpaid with respect to Company’s
outstanding securities.
2.3.2 Options/Rights.
An
aggregate of 2,600,000 shares of Company Common Stock are reserved and
authorized for issuance pursuant to the Company Stock Plan, of which options
to
purchase a total of 1,797,312 shares of Company Common Stock are outstanding.
Except
for (i) the Xxxxxx Option, (ii) those options outstanding under the Company
Stock Plan, and (iii) as disclosed in Section 2.3.2
of the
Company Disclosure Schedule, there are no stock appreciation rights, options,
warrants, calls, rights, commitments, conversion privileges or preemptive or
other rights or agreements outstanding to purchase or otherwise acquire any
of
Company’s authorized but unissued capital stock or any securities or debt
convertible into or exchangeable for shares of Company Preferred Stock and
Company Common Stock or obligating Company to grant, extend or enter into such
option, warrant, call, commitment, conversion privileges or preemptive or other
right or agreement. Company
has delivered to Buyer a correct and complete list of each Company Option and
Company Warrant outstanding as of the date hereof, including the name of the
holder of such Company Option or Company Warrant, the number of shares covered
by such Company Option or Company Warrant, the per share exercise price of
such
Company Option or Company Warrant and the vesting commencement date and vesting
schedule applicable to each such Company Option, including the number of shares
vested as of the date of this Agreement. Except as set forth in Section
2.3.2
of the
Company Disclosure Schedule and Exhibit
B,
no
other outstanding option,
warrant, call, commitment, conversion privileges or preemptive or other right
or
agreement,
whether
under the Company Stock Plan or otherwise, will be accelerated in connection
with the Merger. Any
acceleration of options to purchase Company Common Stock has been done in
accordance with the terms of the Company Plan or with the consent or approval
of
the holders of such securities.
9
2.4 Securityholder
Lists and Agreements.
2.4.1 Included
as Section 2.4.1
of the
Company Disclosure Schedule is a true, complete and correct list of all of
Company Securityholders, including holders of Company Stock,
holders
of Company Options, Company Warrants and Convertible Debentures, showing the
shares of Company Stock or other securities of the Company held by each such
Company Securityholder as of the date of this Agreement, and the number of
shares of Company Common Stock into which such securities are convertible or
exercisable.
2.4.2 Except
as
provided in the Company’s Certificate of Incorporation, as amended, this
Agreement or the Company Disclosure Schedule, there are no agreements, written
or oral, between the Company and any holder of its securities or among any
holders of the Company's securities relating to the acquisition (including
without limitation rights of first refusal, anti-dilution or pre-emptive
rights), disposition, registration under the Securities Act or voting of the
capital stock of the Company.
2.5 Subsidiaries.
Upon
completion of the Spinoff (as defined in Section 4.17 below), the Company will
not have any subsidiaries or any interest, direct or indirect, in any
corporation, partnership, joint venture or other business entity.
2.6 No
Violation of Existing Agreements.
Neither
the execution and delivery of this Agreement nor any Company Ancillary
Agreement, nor the consummation of the transactions contemplated hereby, will
conflict with, or (with or without notice or lapse of time, or both) result
in a
termination, breach, impairment or violation of (a) any provision of the
certificate of incorporation or bylaws of Company, as currently in effect,
(b) in any material respect, any material instrument or contract to which
Company is a party or by which Company is bound, or (c) any federal, state,
local or foreign judgment, writ, decree, order, statute, rule or regulation
applicable to Company or its assets or properties. Except
as
set forth on the Company Disclosure Schedule, the consummation of the Merger
and
the transfer to Buyer of all material rights, licenses, franchises, leases
and
agreements of Company will not require the consent of any third
party.
10
2.7 Litigation.
There
is no action, proceeding, claim or investigation pending against Company before
any court or administrative agency that if determined adversely to Company
may
reasonably be expected to have a Material Adverse Effect (as defined below)
on
the present or future operations or financial condition of Company, nor, to
the
Company’s Knowledge (as defined below), has any such action, proceeding, claim
or investigation been threatened (collectively, “Actions”).
There
is, to the Company’s Knowledge, no reasonable basis for any stockholder or
former stockholder of Company, or any other person, firm, corporation, or
entity, to assert a claim against Company or Buyer based upon: (a) ownership
or
rights to ownership of any shares of Company Stock (except for dissenter’s
rights with respect to shares of Buyer Common Stock issuable by virtue of the
Merger), (b) any rights as a Company Securityholder, including any option or
preemptive rights or rights to notice or to vote, or (c) any rights under any
agreement among Company and its stockholders.
For
purposes of this Agreement, the term “Material
Adverse Effect”
when
used in connection with an entity means any change, event or effect whether
or
not such change, event or effect is caused by or arises in connection with
a
breach of a representation, warranty, covenant or agreement of such entity
in
this Agreement that is or is reasonably likely to be materially adverse to
the
business, assets (including intangible assets), capitalization, financial
condition, operations or results of operations of such entity taken as a whole,
except to the extent that any such change, event, circumstance or effect solely
results from (i) changes in general economic conditions, or (ii) changes
affecting the industry generally in which such entity operates (provided that
such changes do not affect such entity in a substantially disproportionate
manner).
For
purposes of this Agreement the term “Knowledge”
means
with respect to a party hereto, with respect to any matter in question, that
any
of the officers of such party has actual knowledge of such matter.
2.8 Taxes.
(a)
Company has filed all federal, state, local and foreign tax returns required
to
be filed, which returns are true, correct and complete in all material respects,
has paid all taxes required to be paid in respect of all periods for which
returns have been filed, has established an adequate accrual or reserve for
the
payment of all taxes payable in respect of the periods subsequent to the periods
covered by the most recent applicable tax returns, and has made all necessary
estimated tax payments. Company is not delinquent in the payment of any tax
or
in the filing of any tax returns, and no deficiencies for any tax have been
threatened, claimed, proposed or assessed. There are no liens for taxes (other
than taxes not yet due and payable) on any of the assets of the Company. The
Company is not currently the beneficiary of any extension of time within which
to file any tax return. The Company has delivered to Buyer correct and complete
copies of all federal income tax returns, examination reports and statements
of
deficiencies assessed against or agreed to by the Company since December 31,
2001. No tax return of Company has ever been audited by the Internal Revenue
Service or any state taxing agency or authority. For the purposes of this
Section, the terms “tax”
and
“taxes”
include
all federal, state, local and foreign income, gains, franchise, excise,
property, sales, use, employment, license, payroll, occupation, recording,
value
added or transfer taxes, governmental charges, fees, levies or assessments
(whether payable directly or by withholding), and, with respect to such taxes,
any estimated tax, interest and penalties or additions to tax and interest
on
such penalties and additions to tax.
11
(b) None
of
the Company or any of its subsidiaries is a party to any agreement, contract,
arrangement or plan that has resulted or would result, separately or in the
aggregate, in the payment of any “excess parachute payment” within the meaning
of Code Section 280G (or any corresponding provision of state, local or foreign
tax law). None of the company or any of its subsidiaries has been a U.S. real
property holding corporation within the meaning of Code Section 897(c)(2) during
the applicable period specified in Code Section 897(c)(1)(A)(ii). None of the
Company or any of its subsidiaries (A) is a party to or bound by any tax
allocation or sharing agreement, (B) has been a member of an affiliated group
filing a consolidated federal income tax return (other than a group of which
the
common parent was the Company) or (C) has any liability for the taxes of any
person (other than the Company or its subsidiaries) under Treasury Regulations
section 1.1502-6 (or any similar provision of state, local or foreign law),
as a
transferee or successor, by contract, or otherwise.
(c) None
of
the Company or its subsidiaries (other than Spinco after the Spinoff) will
be
required to include any item of income in, or exclude any item of deduction
from, taxable income for any taxable period ending after the Closing Date as
a
result of any
(i)
|
change
in method of accounting for a taxable period ending on or prior to
the
Closing Date;
|
(ii)
|
any
“Closing Agreement” as described on Code Section 7121 (or any
corresponding or similar provision of state, local or foreign income
tax
law);
|
(iii)
|
intercompany
transactions or any excess loss account described in Treasury Regulations
under Code Section 1502 (or any corresponding or similar provision
of
state, local or foreign income tax
law);
|
(iv)
|
installment
sale or open transaction disposition made on or prior to the Closing
Date;
or
|
(v)
|
prepaid
amount received on or prior to the Closing
Date.
|
(d) The
unpaid taxes of the Company and its subsidiaries did not as of the date of
the
Company Balance Sheet exceed the reserve for tax liability (rather than any
reserve for deferred taxes established to reflect timing differences between
book and tax income) set forth on the face of such Balance Sheet (rather than
in
any notes thereto) and will not exceed that reserve as adjusted for operations
and transactions in the ordinary course of the Company’s business through the
Closing Date in accordance with the past custom and practice of the Company
and
its subsidiaries in filing their tax returns.
12
2.9 Company
Financial Statements.
Attached as Section 2.9
of the
Company Disclosure Schedule are true, complete and correct copies of the
following financial statements (collectively, the “Company
Financial Statements”):
(i)
the Company’s audited balance sheet as of December 31, 2005 and December 31,
2004 and income statement and statement of cash flows for the years then ended
and (ii) the Company’s unaudited balance sheet (the “Company
Balance Sheet”),
statement of cash flows and income statement each dated as of August 31, 2006.
The Company Financial Statements (a) are in accordance with the books and
records of Company, (b) fairly present the financial condition of Company at
the
date therein indicated and the results of operations for the period therein
specified and (c) have been prepared in accordance with generally accepted
accounting principles applied on a consistent basis (except
that the Company Balance Sheet lacks footnotes and other presentation items
and
is subject to normally-recurring year-end audit adjustments).
Except
as set forth on the Company Disclosure Schedule, Company has no material debt,
liability or obligation of any nature, whether accrued, absolute, contingent
or
otherwise, and whether due or to become due, that is not reflected or reserved
against in the Company Financial Statements, except for expenses incurred in
connection with the transactions contemplated by this Agreement and those that
may have been incurred after the date of the Company Financial Statements in
the
ordinary course of its business, consistent with past practice and that are
not
material in amount either individually or collectively.
2.10 Title
to Properties.
Except
as set forth on the Company Disclosure Schedule and except for those assets
included in the Spinoff, the Company has good and marketable title to all of
its
assets as shown on the Company Balance Sheet, free and clear of all liens,
charges, restrictions or encumbrances (other than for taxes not yet due and
payable). All machinery and equipment included in such properties is in good
condition and repair, normal wear and tear excepted, and all leases of real
or
personal property to which Company is a party are fully effective and affords
Company peaceful and undisturbed possession of the subject matter of the lease.
Company is not in violation of any zoning, building, safety or environmental
ordinance, regulation or requirement or other law or regulation applicable
to
the operation of the Company’s owned or leased properties (the violation of
which would have a Material Adverse Effect on its business), nor has the Company
received any notice of violation with which it has not complied.
2.11 Absence
of Certain Changes.
Except
as set forth on the Company Disclosure Schedule, since the date of the Company
Balance Sheet, there has not been with respect to Company:
(a) Except
for the disposition of assets, liabilities and business expressly contemplated
by the Spinoff, any change in the financial condition, properties, assets,
liabilities, business or operations thereof which change by itself or in
conjunction with all other such changes, whether or not arising in the ordinary
course of business, has had or will have a Material Adverse Effect
thereon;
(b) any
contingent liability incurred thereby as guarantor or otherwise with respect
to
the obligations of others;
(c) any
mortgage, pledge, encumbrance or lien placed on any of the properties or assets,
tangible or intangible, thereof;
13
(d) any
material obligation or liability incurred thereby other than obligations and
liabilities incurred in the ordinary course of business;
(e) except
for any disposition of assets expressly contemplated by the Spinoff, any
purchase or sale or other disposition, or any agreement or other arrangement
for
the purchase, sale or other disposition, of any of the properties or assets
thereof other than in the ordinary course of business;
(f) any
damage, destruction or loss, whether or not covered by insurance, materially
and
adversely affecting the properties, assets or business thereof;
(g) except
for any disposition of assets or stock dividend expressly contemplated by the
Spinoff, any declaration, setting aside or payment of any dividend on, or the
making of any other distribution in respect of, the capital stock thereof,
any
split, combination or recapitalization of the capital stock thereof or any
direct or indirect redemption, purchase or other acquisition of the capital
stock thereof;
(h) any
labor
dispute or claim of unfair labor practices, any change in the compensation
payable or to become payable to any of its officers, employees or agents, or
any
bonus payment or arrangement made to or with any of such officers, employees
or
agents;
(i) except
as
expressly contemplated as part of the Spinoff, any change with respect to the
management, supervisory or other key personnel thereof;
(j) except
as
expressly contemplated by the Spinoff, any payment or discharge of a material
lien or liability thereof which lien was not either shown on the Company Balance
Sheet or incurred in the ordinary course of business thereafter;
(k) except
as
expressly contemplated by the Spinoff, any obligation or liability incurred
thereby to any of its officers, directors or stockholders or any loans or
advances made thereby to any of its officers, directors or stockholders except
normal compensation and expense allowances payable to officers; or
(l) except
as
expressly contemplated as part of the Spinoff, any agreement to do any of the
foregoing.
2.12 Contracts
and Commitments.
Except
as set forth on Section 2.12
of the
Company Disclosure Schedule delivered to Buyer herewith, and after giving effect
to the Spinoff, the Company is not a party to any contract, obligation or
commitment which is material to the business of Company which involves a
potential commitment in excess of $10,000 or any stock redemption or purchase
agreement, financing agreement, license, lease or franchise. A copy of each
agreement or document listed on Section 2.12
of the
Company Disclosure Schedule has been delivered to Buyer or Buyer’s counsel.
Company is not in default in any material respect under any contract, obligation
or commitment listed on Section 2.12
of the
Company Disclosure Schedule or that is otherwise material to the business of
Company. Company does not have any material liability for renegotiation of
government contracts or subcontracts.
14
2.13 Intellectual
Property.
2.13.1 Section
2.13.1
of the
Company Disclosure Schedule sets forth true, complete and correct lists
of:
(a) all
patents and pending patent applications;
(b) all
trademark registrations (including Internet domain name registrations) and
pending trademark applications; and
(c) all
copyright registrations and pending copyright applications
owned
by
the Company or that the Company has licensed and that is material to the
business of the Company, as of the date of this Agreement, after giving effect
to the Spinoff (collectively, the “Company
Registered Intellectual Property”).
2.13.2 Except
as
set forth in the Company Disclosure Schedule, all of the Company Registered
Intellectual Property is owned by or exclusively licensed to the
Company.
2.13.3 All
of
the Company Registered Intellectual Property is valid, subsisting, in full
force
and effect (except with respect to applications), and has not expired or been
canceled or abandoned.
2.13.4 There
is
no pending or, to the Knowledge of the Company, threatened (and at no time
within the two years prior to the date of this Agreement has there been pending
any) Action before any court, government agency or arbitral tribunal in any
jurisdiction challenging the use, ownership, validity, enforceability or
registerability of any of Company Registered Intellectual Property. Neither
the
Company, nor to the Knowledge of the Company, any of its licensors, is a party
to any settlements, covenants not to xxx, consents, decrees, stipulations,
judgments or orders resulting from Actions which permit third parties to use
any
of the Company Registered Intellectual Property.
2.13.5 The
Company owns, or has valid rights to use, all of the Intellectual Property
used
in the business of the Company as currently conducted, after giving effect
to
the Spinoff.
2.13.6 After
giving effect to the Spinoff, the owned Company Registered Intellectual Property
does not unlawfully infringe and, to the Knowledge of the Company no other
Company Registered Intellectual Property unlawfully infringes, upon any
Intellectual Property or other proprietary right owned by any third
party.
2.13.7 To
the
Company’s Knowledge, no third party is misappropriating, infringing or violating
any Intellectual Property owned by, or licensed to, the Company that is material
to the business of the Company as currently conducted, after giving effect
to
the Spinoff, and no Intellectual Property or other proprietary right
misappropriation, infringement or violation Actions have been brought against
any third party by the Company which remain unresolved.
15
2.13.8 There
is
no pending or, to the Knowledge of the Company, threatened (and at no time
within the two years prior to the date of this Agreement has there been pending
any) Action alleging that the activities or the conduct of the Company’s
business dilutes, misappropriates, infringes, violates or constitutes the
unauthorized use of, or will dilute, misappropriate, infringe upon, violate
or
constitute the unauthorized use of the Intellectual Property of any third party.
The Company is not party to any settlements, covenants not to xxx, consents,
decrees, stipulations, judgments, or orders resulting from any Action which
(i)
restricts the Company’s rights to use any Intellectual Property, (ii) restricts
the Company’s business in order to accommodate a third party’s Intellectual
Property or (iii) requires any future payment by the Company.
2.13.9 The
Company requires each new relevant employee to execute a noncompetition,
nonsolicitation, nondisclosure and developments agreement in the Company’s
standard form as set forth in Section 2.13.9
of the
Company Disclosure Schedule. Other than under an appropriate confidentiality
or
nondisclosure agreement or contractual provision relating to confidentiality
and
nondisclosure, there has been no disclosure to any third party of material
confidential information or trade secrets of the Company related to any material
proprietary product currently being marketed, sold, licensed or developed by
the
Company, after giving effect to the Spinoff (each such product, a “Proprietary
Product”).
All
employees of the Company who have made material contributions to the development
of any Proprietary Product have signed noncompetition, nonsolicitation,
nondisclosure and developments agreements substantially in the form attached
to
Section 2.13.9
of the
Company Disclosure Schedule. All consultants and independent contractors who
have made material contributions to the development of any Proprietary Product
have entered into a work-made-for-hire agreement or have otherwise assigned
to
the Company (or a third party that previously conducted any business currently
conducted by the Company and that has assigned its rights in such Proprietary
Product to the Company) all of their right, title and interest (other than
moral
rights, if any) in and to the portions of such Proprietary Product developed
by
them in the course of their work for the Company. Assignments of the patents,
patent applications, copyrights and copyright applications listed in Section
2.13.1
of the
Company Disclosure Schedule to the Company have been duly executed and filed
with the United States Patent and Trademark Office or Copyright Office, as
applicable.
2.13.10 Except
as
set forth on the Company Disclosure Schedule and after giving effect to the
Spinoff, the Company does not have any obligation to pay any third party any
future royalties or other fees for the continued use of Intellectual Property
and the Company will not have any obligation to pay such royalties or other
fees
arising from the consummation of the transactions contemplated by this
Agreement.
2.13.11 The
Company is not in material violation of any Contract to which the Company is
party or otherwise bound, nor will the consummation by the Company of the
transactions contemplated hereby, result in any material violation, loss or
impairment of ownership by the Company of, or the right of the Company to use,
any Intellectual Property that is material to the business of the Company as
currently conducted, after giving effect to the Spinoff, nor require the consent
of any Governmental Authority or third party with respect to any such
Intellectual Property. The Company is not a party to any Contract under which
a
third party would have or would be entitled to receive a license or any other
right to any Intellectual Property of Buyer or any of Buyer’s affiliates as a
result of the consummation of the transactions contemplated by this Agreement
nor would the consummation of such transactions result in the amendment or
alteration of any such license or other right which exists on the date of this
Agreement.
16
2.13.12 For
purposes of this Agreement, “Intellectual
Property”
shall
mean trademarks, service marks, trade names, slogans, logos, trade dress,
internet domain names and other similar designations of source or origin,
together with all goodwill, registrations and applications related to the
foregoing; patents, utility, models and industrial design registrations or
applications (including without limitation any continuations, divisionals,
continuations-in-part, provisionals, renewals, reissues, re-examinations and
applications for any of the foregoing); copyrights and copyrightable subject
matter (including without limitation any registration and applications for
any
of the foregoing, but excluding any off-the-shelf software); mask works rights
and trade secrets and other confidential information, know-how, proprietary
processes, formulae, algorithms, models, and methodologies; and computer
programs (whether in source code, object code or other form) in each case used
in or necessary for the conduct of the business of the party making such
representation, as currently conducted and as planned to be conducted, whether
such Intellectual Property is owned by such party or a third party.
2.14 Compliance
with Laws.
Company
has complied, or prior to the Closing Date will have complied, and is or will
be
at the Closing Date in full compliance, in all material respects with all
applicable laws, ordinances, regulations, and rules, and all orders, writs,
injunctions, awards, judgments, and decrees applicable to it or to the assets,
properties, and business thereof (the violation of which would have a Material
Adverse Effect upon its business), including, without limitation: (a) all
applicable federal and state securities laws and regulations, (b) all
applicable federal, state, and local laws, ordinances, regulations, and all
orders, writs, injunctions, awards, judgments, and decrees pertaining to
(i) the sale, licensing, leasing, ownership, or management of its owned,
leased or licensed real or personal property, products and technical data,
(ii) employment and employment practices, terms and conditions of
employment, and wages and hours and (iii) safety, health, fire prevention,
environmental protection, toxic waste disposal, building standards, zoning
and
other similar matters (c) the Export Administration Act and regulations
promulgated thereunder and all other laws, regulations, rules, orders, writs,
injunctions, judgments and decrees applicable to the export or re-export of
controlled commodities or technical data and (d) the Immigration Reform and
Control Act. Company has received all permits and approvals from, and has made
all filings with, third parties, including government agencies and authorities,
that are necessary in connection with its present business. There are no legal
or administrative proceedings or investigations pending or threatened, that,
if
enacted or determined adversely to Company, would result in any material adverse
change in the present or future operations or financial condition
thereof.
17
2.15 Certain
Transactions and Agreements.
2.15.1 None
of
the officers or directors of Company, nor any member of their immediate
families, has any direct or indirect ownership interest in any firm or
corporation that competes with Company (except with respect to any interest
in
less than one percent of the stock of any corporation whose stock is publicly
traded). After giving effect to the Spinoff, none of said officers or directors,
or any member of their immediate families, is directly or indirectly interested
in any contract or informal arrangement with Company, except for normal
compensation for services as an officer, director or employee thereof. None
of
said officers or directors or family members has any interest in any property,
real or personal, tangible or intangible, including inventions, patents,
copyrights, trademarks or trade names or trade secrets, used in or pertaining
to
the business of Company, except for the normal rights of a
stockholder.
2.15.2 No
officer or director of Company or any “affiliate” or “associate” (as those terms
are defined in Rule 405 promulgated under the Securities Act) of any such person
has had, either directory or indirectly, a material interest in: (i) any person
or entity which purchases from or sells, licenses or furnishes to Company any
goods, property, technology or intellectual or other property rights or
services; or (ii) any contract or agreement to which Company is a party or
by
which it may be bound or affected.
2.16 Benefit
Plans.
2.16.1 For
purposes of this Agreement,
the term
“Plan”
means
any employee benefit plan (as defined in Section 3(3) of the Employee Retirement
Income Security Act of 1974, as amended (“ERISA”),
whether or not subject to ERISA), any other bonus, profit sharing, compensation,
pension, retirement, “401(k),” “SERP,” severance, savings, deferred
compensation, fringe benefit, insurance, welfare, post-retirement health or
welfare benefit, health, life, stock option, stock purchase, restricted stock,
tuition refund, service award, company car or car allowance, scholarship,
housing or living allowances, relocation, disability, accident, sick pay, sick
leave, accrued leave, vacation, holiday, termination, unemployment, individual
employment, consulting, executive compensation, incentive, commission, payroll
practices, retention, change in control, non-competition, other material plan,
agreement, policy, trust fund or arrangement (whether written or unwritten,
insured or self-insured), and any plan subject to Sections 125, 127, 129, 137
or
423 of the Code, currently maintained, sponsored or contributed to by an entity
or any trade or business, whether or not incorporated, that together with the
entity would be deemed to be a “single employer” within the meaning of Section
4001(b) of ERISA (an “ERISA
Affiliate”).
Each
Company Plan is in writing. Section 2.16.1
of the
Company Disclosure Schedule includes a true and complete list of all Company
Plans, and the Company has provided or made available to Buyer a complete copy
of each Company Plan as well as, if applicable, a copy of each trust or other
funding arrangement, each summary plan description and summary of material
modifications, the most recent application for determination letter submitted
to
the IRS and the most recent determination letter received from the IRS. The
Company has made available to Buyer true and complete copies of all Form 5500
Series annual reports for each Company Plan in respect of each of the last
three
full plan years, together with all schedules, attachments, and related opinions
and copies of any correspondence from or to the IRS, the Department of Labor
or
other U.S. government departments or agencies relating to an audit or penalty
assessment with respect to any Company Plan or relating to requested relief
from
any liability or penalty relating to any Company Plan.
18
2.16.2 The
Company is and has been in material compliance with the terms of each Company
Plan.
2.16.3 Each
Company Plan and each funding vehicle related to such Plan is currently in
compliance in all material respects with, and has been administered and operated
in compliance in all material respects with, its terms and all applicable
statutes, orders, rules and regulations. Each Company Plan which is intended
to
be a “qualified plan” as described in Section 401(a) of the Code has been
determined by the IRS to so qualify, and to the Knowledge of the Company there
are no facts which might adversely affect such qualification.
2.16.4 Neither
the Company nor its ERISA Affiliates maintains, sponsors or contributes to
any
single employer plan (as such term is defined in Section 4001(b) of ERISA)
subject to Title IV of ERISA or any “multiemployer plan” (as such term is
defined in Section 3(37) of ERISA), nor have they incurred any material
liability, including without limitation withdrawal liability, with respect
to
any such Plan that remains unsatisfied.
2.16.5 No
Company Plan is funded by, associated with or related to a “voluntary employees’
beneficiary association” within the meaning of Section 501(c)(9) of the
Code.
2.16.6 The
Company has made or will accrue prior to the Closing Date all payments and
contributions (including insurance premiums) due and payable as of the Closing
Date to each Company Plan as required to be made under the terms of such
Plan.
2.16.7 To
the
Knowledge of the Company, with respect to all Company Plans and related trusts,
there are no “prohibited transactions,” as that term is defined in Section 406
of ERISA or Section 4975 of the Code, that have occurred which could subject
any
Company Plan, related trust or party dealing with any such Plan or related
trust
to any tax or penalty on prohibited transactions imposed by Section 501(i)
of
ERISA or Section 4975 of the Code.
2.16.8 There
are
no actions, suits, arbitrations or claims (other than routine claims for
benefits by employees of the Company, beneficiaries or dependents of such
employees arising in the normal course of operation of a Company Plan) pending,
or to the Knowledge of the Company, threatened, with respect to any Company
Plan
or any fiduciary or sponsor of a Company Plan with respect to their duties
under
such Plan or the assets of any trust under any such Plan.
2.16.9 The
Company has complied in all material respects with the health care continuation
requirements of Section 601, et. seq. of ERISA with respect to employees and
their spouses, former spouses and dependents.
2.16.10 The
Company does not have any obligations under any Company Plan to provide
post-retirement medical benefits to any employee or any former employee of
the
Company other than statutory liability for providing group health plan
continuation coverage under Part 6 of Title I of ERISA and Section 4980B of
the
Code or applicable state law.
19
2.16.11 Neither
the negotiation and execution of this Agreement, nor the consummation of the
transactions contemplated by this Agreement will, either alone or in combination
with another event, (i) entitle any current or former employee or officer of
the
Company or any ERISA Affiliate to severance pay, unemployment compensation
or
any other payment, except as expressly provided in this Agreement, or (ii)
accelerate the time of payment or vesting, or increase the amount of
compensation due any such employee or officer.
2.16.12 The
Company is not a party to, or otherwise obligated under, any contract,
agreement, plan or arrangement covering any person that, individually or
collectively, could give rise to the payment of any amount that would not be
deductible by Parent, the Company or any of their respective affiliates by
reason of Section 280G of the Code or that could be subject to Section 4999
of
the Code.
2.17 Corporate
Documents.
Company
has made available to Buyer for examination all documents and information listed
in the Company Disclosure Schedule, other Exhibits called for by this Agreement
and documents requested by Buyer’s legal counsel, including, without limitation,
the following: (a) copies of Company’s certificate of incorporation and bylaws
as currently in effect; (b) its Minute Book containing all records of all
proceedings, consents, actions, and meetings of the stockholders, the board
of
directors and any committees thereof; (c) its stock ledger and journal
reflecting all stock issuances and transfers; and (d) all permits, orders,
and
consents issued by any regulatory agency with respect to Company, or any
securities of Company, and all applications for such permits, orders, and
consents.
2.18 No
Brokers.
Neither
Company nor any of the Company Securityholders is obligated for the payment
of
fees or expenses of any investment banker, broker or finder in connection with
the origin, negotiation or execution of this Agreement or the Certificates
of
Merger or in connection with any transaction contemplated hereby or
thereby.
2.19 Certain
Material Agreements.
Except
as set forth on the Company Disclosure Schedule and after giving effect to
the
Spinoff, the Company is not a party or subject to any oral or written material
contracts not entered into in the ordinary course of business, including, but
not limited to any:
(a) Contract
providing for payments by or to Company in an aggregate amount of $10,000 or
more;
(b) License
agreement as licensor or licensee (except for standard non-exclusive hardware
and software licenses granted to end-user customers in the ordinary course
of
business the form of which has been provided to Buyer’s counsel);
(c) Material
agreement for the lease of real or personal property;
(d) Joint
venture contract or arrangement or any other agreement that involves a sharing
of profits with other persons;
20
(e) Instrument
evidencing or related in any way to indebtedness for borrowed money by way
of
direct loan, sale of debt securities, purchase money obligation, conditional
sale, guarantee, or otherwise, except for trade indebtedness incurred in the
ordinary course of business, and except as disclosed in the Financial
Statements; or
(f) Contract
containing covenants purporting to limit Company’s freedom to compete in any
line of business in any geographic area.
All
agreements, contracts, plans, leases, instruments, arrangements, licenses and
commitments listed on Section 2.19
of the
Company Disclosure Schedule are valid and in full force and effect. Company
is
not, nor, to the Knowledge of Company, is any other party thereto, in breach
or
default in any material respect under the terms of any such agreement, contract,
plan, lease, instrument, arrangement, license or commitment, which breach or
default may reasonably be expected to have a Material Adverse Effect on
Company.
2.20 Books
and Records.
2.20.1 The
books, records and accounts of Company (a) are in all material respects true,
complete and correct, (b) have been maintained in accordance with good business
practices on a basis consistent with prior years, (c) are stated in reasonable
detail and accurately and fairly reflect the transactions and dispositions
of
the assets of Company, and (d) accurately and fairly reflect the basis for
the
Financial Statements.
2.20.2 Company
has devised and maintains a system of internal accounting controls sufficient
to
provide reasonable assurances that (a) transactions are executed in accordance
with management’s general or specific authorization; (b) transactions are
recorded as necessary (i) to permit preparation of financial statements in
conformity with generally accepted accounting principles or any other criteria
applicable to such statements, and (ii) to maintain accountability for assets,
and (c) the amount recorded for assets on the books and records of Company
is
compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences.
2.21 Insurance.
Section
2.21 of the Company Disclosure Schedule contains a complete and correct list
as
of the date hereof of all insurance policies maintained by or on behalf of
the
Company. Such list includes the type of policy, form of coverage, policy number
and insurer, coverage dates, named insured, limit of liability and premium
and
deductible amounts. True and complete copies of each listed policy have been
made available to Buyer. Such policies are in full force and effect, all
premiums due thereon have been paid and the Company has complied in all material
respects with the provisions of such policies. The Company has not received
any
notices from any issuer of any of their insurance policies canceling or amending
any policies listed on Section 2.21 of the Company Disclosure Schedule,
increasing any deductibles or retained amounts thereunder, or materially
increasing premiums payable thereunder. There is no claim by the Company pending
under any of such policies as to which coverage has been denied or disputed
by
the underwriters or in respect of which the underwriters have reserved their
rights.
21
2.22 Personnel.
2.22.1 Section
2.22.1
of the
Company Disclosure Schedule sets forth a list of all employees, consultants
or
independent contractors of the Company as of the date hereof, but after giving
effect to the Spinoff, including, as of such date their title, base salary
for
2006, all compensation paid in or relating to the year ended December 31, 2005,
including bonus compensation.
2.22.2 The
Company is not subject to any collective bargaining agreement or other labor
union contract, and no employee of the Company is represented by a labor union.
There is not pending or, to the Company’s Knowledge, threatened, any picketing,
strike, labor dispute, slowdown, lockout, walkout, work stoppage or other
similar labor dispute involving employees of the Company, and no union
organizing activities are taking place with respect to such employees or have
taken place within the past two years.
2.22.3 To
the
Company’s Knowledge, except as expressly contemplated as part of the Spinoff,
none of the Company’s officers or key employees or independent contractors
intend to terminate his or her relationship with the Company for any reason,
including, without limitation, as a result of the transactions contemplated
hereby.
2.23 Environmental
Matters.
2.23.1 During
the period that Company has leased or owned its properties or owned or operated
any facilities, there have been no disposals, releases or threatened releases
of
Hazardous Materials (as defined below) on, from or under such properties or
facilities. Company has no Knowledge of any presence, disposals, releases or
threatened releases of Hazardous Materials on, from or under any of such
properties or facilities, which may have occurred prior to Company having taken
possession of any of such properties or facilities. For the purposes of this
Agreement, the terms “disposal”
“release,”
and
“threatened
release”
shall
have the definitions assigned thereto by the Comprehensive Environmental
Response, Compensation and Liability Act of 1980, 42 U.S.C. § 9601 et seq., as
amended (“CERCLA”).
For
the purposes of this Agreement “Hazardous
Materials”
shall
mean any hazardous or toxic substance, material or waste which is or becomes
prior to the Closing regulated under, or defined as a “hazardous substance,”
“pollutant,” “contaminant,” “toxic chemical,” “hazardous materials,” “toxic
substance” or “hazardous chemical” under (1) CERCLA; (2) any similar federal,
state or local law; or (3) regulations promulgated under any of the above laws
or statutes.
2.23.2 To
the
Knowledge of the Company, none of the properties or facilities of Company is
in
violation of any federal, state or local law, ordinance, regulation or order
relating to industrial hygiene or to the environmental conditions on, under
or
about such properties or facilities, including, but not limited to, soil and
ground water condition. During the time that Company has owned or leased its
properties and facilities, neither Company, nor, to Company’s Knowledge, any
third party, has used, generated, manufactured or stored on, under or about
such
properties or facilities or transported to or from such properties or facilities
any Hazardous Materials.
22
2.23.3 During
the time that Company has owned or leased their respective properties and
facilities, there has been no litigation brought or threatened against Company
by, or any settlement reached by Company with, any party or parties alleging
the
presence, disposal, release or threatened release of any Hazardous Materials
on,
from or under any of such properties or facilities.
2.24 Vote
Required.
The
affirmative
votes of the holders of: (a) at least a majority of the outstanding shares
of
the Company’s Series A Preferred Stock, (b) at least 55% of the outstanding
shares of the Company’s Series B Preferred Stock, (c) at least 55% of the
outstanding shares of the Company’s Series A Preferred Stock and Series B
Preferred Stock voting together as a single class, and (d) at least a majority
of the outstanding shares of the Company’s Common Stock, Series A Preferred
Stock (on an as-converted to common stock basis) and Series B Preferred Stock
(on an as-converted to common stock basis), all voting together as a single
class,
are the
only votes of the holders of any of the Company’s capital stock necessary to
approve this Agreement and the transactions contemplated hereby (collectively,
the “Requisite
Stockholder Approval”).
2.25 Board
Approval.
The
board of directors of the Company has unanimously (a) approved and adopted
this
Agreement and approved the Merger, (b) determined that the Merger is in the
best
interests of the Company stockholders and (c) recommended that the Company
stockholders approve this Agreement and the Merger. None of such actions taken
by the board of directors of the Company has been amended, rescinded or
modified.
2.26 Anti-Takeover
Statute Not Applicable.
No
“business combination,” “fair price,” “moratorium,” “control share acquisition”
or other similar anti-takeover statute or regulation or anti-takeover provision
in the Company Organizational Documents is applicable to this Agreement, the
Merger or any of the other transactions contemplated by this
Agreement.
2.27 Disclosure.
None of
the representations of the Company in this Agreement, its exhibits and
schedules, nor any of the certificates or documents to be delivered by Company
to Buyer under this Agreement, taken together, contains any untrue statement
of
a material fact or omits to state any material fact necessary in order to make
the statements contained herein and therein, in light of the circumstances
under
which such statements were made, not misleading.
3.
|
REPRESENTATIONS
AND WARRANTIES OF BUYER
|
Except
as
set forth on the Buyer Disclosure Letter
delivered to Company (the “Buyer
Disclosure Schedule”),
Buyer
hereby represents and warrants, as set forth in this Section 3. The Buyer
Disclosure Schedule shall be arranged in Sections and Subsections corresponding
to the numbered Sections and Subsections contained in this Section 3. The
disclosures in any Section of the Disclosure Schedule shall qualify (i) the
corresponding Subsection in this Section 3, and (ii) other Subsections in this
Section 3 to the extent it is reasonable from a reading of the disclosure
(notwithstanding the absence of a specific cross reference) that such disclosure
is applicable to such other Subsections. Unless the context otherwise requires,
references in this Section 3 to the “Buyer” shall include all of the Buyer’s
direct and indirect subsidiaries.
23
3.1 Organization
and Good Standing.
Buyer
is a corporation duly organized, validly existing and in good standing under
the
laws of the State of Delaware, and has the corporate power and authority to
own,
operate and lease its properties and to carry on its business as now conducted
and as proposed to be conducted.
3.2 Power,
Authorization and Validity.
3.2.1 Buyer
has
the right, power, legal capacity and authority to enter into and perform its
obligations under this Agreement, and all agreements to which Buyer is or will
be a party that are required to be executed pursuant to this Agreement (the
“Buyer
Ancillary Agreements”).
The
execution, delivery and performance of this Agreement and the Buyer Ancillary
Agreements have been duly and validly approved and authorized by Buyer’s board
of directors in compliance with applicable law and the certificate of
incorporation and bylaws of the Buyer. Buyer has authorized a sufficient number
of shares of its capital stock to effect the terms of the Merger as described
in
this Agreement.
3.2.2 No
filing, authorization or approval, governmental or otherwise, is necessary
to
enable Buyer to enter into, and to perform its obligations under, this Agreement
and the Buyer Ancillary Agreements, except for (a) the filing of the
Certificates of Merger with the Delaware Secretary of State, and the filing
of
appropriate documents with the relevant authorities of other states in which
Buyer is qualified to do business, if any, and (b)
such
filings as may be required to comply with federal and state securities
laws.
3.2.3 This
Agreement and the Buyer Ancillary Agreements are, or when executed by Buyer
will
be, valid and binding obligations of Buyer enforceable in accordance with their
respective terms, except as to the effect, if any, of (a) applicable bankruptcy
and other similar laws affecting the rights of creditors generally, (b) rules
of
law governing specific performance, injunctive relief and other equitable
remedies and (c) the enforceability of provisions requiring indemnification
in
connection with the offering, issuance or sale of securities; provided, however,
that the Certificates of Merger will not be effective until filed with the
Delaware of State.
3.3 No
Violation of Existing Agreements.
Neither
the execution and delivery of this Agreement nor any Buyer Ancillary Agreement,
nor the consummation of the transactions contemplated hereby, will conflict
with, or (with or without notice or lapse of time, or both) result in a
termination, breach, impairment or violation of (a) any provision of the
certificate of incorporation or bylaws of Buyer, as currently in effect, (b)
in
any material respect, any material instrument or contract to which Buyer is
a
party or by which Buyer is bound, or (c) any federal, state, local or foreign
judgment, writ, decree, order, statute, rule or regulation applicable to Buyer
or its assets or properties.
3.4 Disclosure.
Buyer
has furnished Company with its annual report on Form 10-KSB for its fiscal
year
ended December 31, 2005, its quarterly report on Form 10-QSB for its fiscal
quarters ended March 31, 2006, June 30, 2006 and September 30, 2006 and all
other reports or documents required to be filed by Buyer pursuant to Section
13(a) or 15(d) of the 1934 Act since the filing of the most recent quarterly
report on Form 10-QSB (the “Buyer
Disclosure Package”),
all
of which were timely filed with the Securities and Exchange Commission and
have
been prepared in all material respects in accordance with the applicable
requirements under the Securities Act and the Exchange Act. The Buyer Disclosure
Package, this Agreement, the exhibits and schedules hereto, and any certificates
or documents to be delivered to Company pursuant to this Agreement, when taken
together, do not contain any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements contained
herein and therein, in light of the circumstances under which such statements
were made, not misleading. Additionally, the financial statements contained
in
the Buyer Disclosure Package fairly and accurately, in all material respects,
represent the financial condition of Buyer at the respective dates specified
therein and the results of operation for the respective periods specified
therein in conformity with generally accepted accounting principles applied
on a
consistent basis.
24
3.5 Buyer
Intellectual Property.
3.5.1 The
Buyer
Disclosure Package sets forth true and correct lists of:
(a) all
patents and patent applications;
(b) all
trademark registrations (including Internet domain name registrations) and
pending trademark applications; and
(c) all
copyright registrations and pending copyright applications;
owned
by
the Buyer or that the Buyer has licensed and that is material to the business
of
the Buyer, as of the date of this Agreement (collectively, “Buyer
Registered Intellectual Property”).
3.5.2 All
of
the Buyer Registered Intellectual Property is valid, subsisting, in full force
and effect (except with respect to applications), and has not expired or been
canceled or abandoned.
3.5.3 There
is
no pending or, to the Knowledge of the Buyer, threatened (and at no time within
the two years prior to the date of this Agreement has there been pending any)
Action before any court, government agency or arbitral tribunal in any
jurisdiction challenging the use, ownership, validity, enforceability or
registerability of any of the Buyer Registered Intellectual Property. Neither
the Buyer, nor to the Knowledge of the Buyer, any of its licensors, is a party
to any settlements, covenants not to xxx, consents, decrees, stipulations,
judgments or orders resulting from Actions which permit third parties to use
any
of the Buyer Registered Intellectual Property.
3.5.4 The
Buyer
owns, or has valid rights to use, all of the Intellectual Property used in
the
business of the Buyer as currently conducted.
3.5.5 The
owned
Buyer Registered Intellectual Property does not unlawfully infringe and, to
the
Knowledge of the Buyer no other Buyer Registered Intellectual Property
unlawfully infringes, upon any Intellectual Property or other proprietary right
owned by any third party.
25
3.5.6 To
the
Buyer’s Knowledge, no third party is misappropriating, infringing or violating
any Intellectual Property owned by, or licensed to, the Buyer that is material
to the business of the Buyer as currently conducted, and no Intellectual
Property or other proprietary right misappropriation, infringement or violation
Actions have been brought against any third party by the Buyer which remain
unresolved.
3.5.7 There
is
no pending or, to the Knowledge of the Buyer, threatened (and at no time within
the two years prior to the date of this Agreement has there been pending any)
Action alleging that the activities or the conduct of the Buyer’s business
dilutes, misappropriates, infringes, violates or constitutes the unauthorized
use of, or will dilute, misappropriate, infringe upon, violate or constitute
the
unauthorized use of the Intellectual Property of any third party. The Buyer
is
not party to any settlements, covenants not to xxx, consents, decrees,
stipulations, judgments, or orders resulting from any Action which (i) restricts
the Buyer’s rights to use any Intellectual Property, (ii) restricts the Buyer’s
business in order to accommodate a third party’s Intellectual Property or (iii)
requires any future payment by the Buyer.
3.5.8 The
Buyer
requires each new relevant employee to execute a noncompetition,
nonsolicitation, nondisclosure and developments agreement in the Buyer’s
standard form. Other than under an appropriate confidentiality or nondisclosure
agreement or contractual provision relating to confidentiality and
nondisclosure, there has been no disclosure to any third party of material
confidential information or trade secrets of the Buyer related to Proprietary
Product. All employees of the Buyer who have made material contributions to
the
development of any Proprietary Product have signed noncompetition,
nonsolicitation, nondisclosure and developments agreements. All consultants
and
independent contractors who have made material contributions to the development
of any Proprietary Product have entered into a work-made-for-hire agreement
or
have otherwise assigned to the Buyer (or a third party that previously conducted
any business currently conducted by the Buyer and that has assigned its rights
in such Proprietary Product to the Buyer) all of their right, title and interest
(other than moral rights, if any) in and to the portions of such Proprietary
Product developed by them in the course of their work for the Buyer. Assignments
of the patents, patent applications, copyrights and copyright applications
of
the Buyer to the Buyer have been duly executed and filed with the United States
Patent and Trademark Office or Copyright Office, as applicable.
3.5.9 The
Buyer
is not in material violation of any Contract to which the Buyer is party or
otherwise bound, nor will the consummation by the Buyer of the transactions
contemplated hereby, resulting in any material violation, loss or impairment
of
ownership by the Buyer of, or the right of the Buyer to use, any Intellectual
Property that is material to the business of the Buyer as currently conducted,
nor require the consent of any Governmental Authority or third party with
respect to any such Intellectual Property. The Buyer is not a party to any
Contract under which a third party would have or would be entitled to receive
a
license or any other right to any Intellectual Property of Buyer or any of
Buyer’s affiliates as a result of the consummation of the transactions
contemplated by this Agreement nor would the consummation of such transactions
result in the amendment or alteration of any such license or other right which
exists on the date of this Agreement.
26
3.6 Absence
of Certain Changes.
Since
June 30, 2006, there has not been any change in the financial condition,
properties, assets, liabilities, business or operations of Buyer which change
by
itself or in conjunction with all other such changes, whether or not arising
in
the ordinary course of business, has had or will have a Material Adverse Effect
thereon.
3.7 No
Brokers.
Buyer
is not obligated for the payment of fees or expenses of any investment banker,
broker or finder in connection with the origin, negotiation or execution of
this
Agreement or the Certificates of Merger or in connection with any transaction
contemplated hereby or thereby.
3.8 Litigation.
There
is no action, proceeding, claim or investigation pending against Buyer before
any court or administrative agency that if determined adversely to Buyer may
reasonably be expected to have a Material Adverse Effect on the present or
future operations or financial condition of Buyer, nor, to the Buyer’s
Knowledge, has any such Action been threatened.
3.9 Taxes.
Buyer
has filed all federal, state, local and foreign tax returns required to be
filed, which returns are true, correct and complete in all material respects,
has paid all taxes required to be paid in respect of all periods for which
returns have been filed, has established an adequate accrual or reserve for
the
payment of all taxes payable in respect of the periods subsequent to the periods
covered by the most recent applicable tax returns, and has made all necessary
estimated tax payments. Buyer is not delinquent in the payment of any tax or
in
the filing of any tax returns, and no deficiencies for any tax have been
threatened, claimed, proposed or assessed. There are no liens for taxes (other
than taxes not yet due and payable) on any of the assets of the Buyer. The
Buyer
is not currently the beneficiary of any extension of time within which to file
any tax return. The Buyer has delivered to the Company correct and complete
copies of all federal income tax returns, examination reports and statement
of
deficiencies assessed against or agreed to by the Buyer since December 31,
2001.
No tax return of Buyer has ever been audited by the Internal Revenue Service
or
any state taxing agency or authority. For the purposes of this Section, the
terms “tax”
and
“taxes”
include
all federal, state, local and foreign income, gains, franchise, excise,
property, sales, use, employment, license, payroll, occupation, recording,
value
added or transfer taxes, governmental charges, fees, levies or assessments
(whether payable directly or by withholding), and, with respect to such taxes,
any estimated tax, interest and penalties or additions to tax and interest
on
such penalties and addition to tax.
3.10 Compliance
with Laws.
Buyer
has complied, or prior to the Closing Date will have complied, and is or will
be
at the Closing Date in full compliance, in all material respects with all
applicable laws, ordinances, regulations, and rules, and all orders, writs,
injunctions, awards, judgments, and decrees applicable to it or to the assets,
properties, and business thereof (the violation of which would have a Material
Adverse Effect upon its business), including, without limitation: (a) all
applicable federal and state securities laws and regulations, (b) all
applicable federal, state, and local laws, ordinances, regulations, and all
orders, writs, injunctions, awards, judgments, and decrees pertaining to
(i) the sale, licensing, leasing, ownership, or management of its owned,
leased or licensed real or personal property, products and technical data,
(ii) employment and employment practices, terms and conditions of
employment, and wages and hours and (iii) safety, health, fire prevention,
environmental protection, toxic waste disposal, building standards, zoning
and
other similar matters (c) the Export Administration Act and regulations
promulgated thereunder and all other laws, regulations, rules, orders, writs,
injunctions, judgments and decrees applicable to the export or re-export of
controlled commodities or technical data and (d) the Immigration Reform and
Control Act. Buyer has received all permits and approvals from, and has made
all
filings with, third parties, including government agencies and authorities,
that
are necessary in connection with its present business. There are no legal or
administrative proceedings or investigations pending or threatened, that, if
enacted or determined adversely to Buyer, would result in any material adverse
change in the present or future operations or financial condition
thereof.
27
3.11 Benefit
Plans.
3.11.1 Each
Buyer Plan is in writing. The Buyer Disclosure Package includes a true and
complete list of all Buyer Plans, and the Buyer has provided or made available
to Buyer a complete copy of each Buyer Plan as well as, if applicable, a copy
of
each trust or other funding arrangement, each summary plan description and
summary of material modifications, the most recent application for determination
letter submitted to the IRS and the most recent determination letter received
from the IRS. The Buyer has made available to Buyer true and complete copies
of
all Form 5500 Series annual reports for each Buyer Plan in respect of each
of
the last three full plan years, together with all schedules, attachments, and
related opinions and copies of any correspondence from or to the IRS, the
Department of Labor or other U.S. government departments or agencies relating
to
an audit or penalty assessment with respect to any Buyer Plan or relating to
requested relief from any liability or penalty relating to any Buyer
Plan.
3.11.2 The
Buyer
is and has been in material compliance with the terms of each Buyer
Plan.
3.11.3 Each
Buyer Plan and each funding vehicle related to such Plan is currently in
compliance in all material respects with, and has been administered and operated
in compliance in all material respects with, its terms and all applicable
statutes, orders, rules and regulations. Each Buyer Plan which is intended
to be
a “qualified plan” as described in Section 401(a) of the Code has been
determined by the IRS to so qualify, and to the Knowledge of the Buyer there
are
no facts which might adversely affect such qualification.
3.11.4 Neither
the Buyer nor its ERISA Affiliates maintains, sponsors or contributes to any
single employer plan (as such term is defined in Section 4001(b) of ERISA)
subject to Title IV of ERISA or any “multiemployer plan” (as such term is
defined in Section 3(37) of ERISA), nor have they incurred any material
liability, including without limitation withdrawal liability, with respect
to
any such Plan that remains unsatisfied.
3.11.5 No
Buyer
Plan is funded by, associated with or related to a “voluntary employees’
beneficiary association” within the meaning of Section 501(c)(9) of the
Code.
28
3.11.6 The
Buyer
has made or will accrue prior to the Closing Date all payments and contributions
(including insurance premiums) due and payable as of the Closing Date to each
Buyer Plan as required to be made under the terms of such Plan.
3.11.7 To
the
Knowledge of the Buyer, with respect to all Buyer Plans and related trusts,
there are no “prohibited transactions,” as that term is defined in Section 406
of ERISA or Section 4975 of the Code, that have occurred which could subject
any
Buyer Plan, related trust or party dealing with any such Plan or related trust
to any tax or penalty on prohibited transactions imposed by Section 501(i)
of
ERISA or Section 4975 of the Code.
3.11.8 There
are
no actions, suits, arbitrations or claims (other than routine claims for
benefits by employees of the Buyer, beneficiaries or dependents of such
employees arising in the normal course of operation of a Buyer Plan) pending,
or
to the Knowledge of the Buyer, threatened, with respect to any Buyer Plan or
any
fiduciary or sponsor of a Buyer Plan with respect to their duties under such
Plan or the assets of any trust under any such Plan.
3.11.9 The
Buyer
has complied in all material respects with the health care continuation
requirements of Section 601, et. seq. of ERISA with respect to employees and
their spouses, former spouses and dependents.
3.11.10 The
Buyer
does not have any obligations under any Buyer Plan to provide post-retirement
medical benefits to any employee or any former employee of the Buyer other
than
statutory liability for providing group health plan continuation coverage under
Part 6 of Title I of ERISA and Section 4980B of the Code or applicable state
law.
3.11.11 Neither
the negotiation and execution of this Agreement, nor the consummation of the
transactions contemplated by this Agreement will, either alone or in combination
with another event, (i) entitle any current or former employee or officer of
the
Buyer or any ERISA Affiliate to severance pay, unemployment compensation or
any
other payment, except as expressly provided in this Agreement, or (ii)
accelerate the time of payment or vesting, or increase the amount of
compensation due any such employee or officer.
3.11.12 The
Buyer
is not a party to, or otherwise obligated under, any contract, agreement, plan
or arrangement covering any person that, individually or collectively, could
give rise to the payment of any amount that would not be deductible by Parent,
the Buyer or any of their respective affiliates by reason of Section 280G of
the
Code or that could be subject to Section 4999 of the Code.
3.12 Environmental
Matters.
3.12.1 During
the period that Buyer has leased or owned its properties or owned or operated
any facilities, there have been no disposals, releases or threatened releases
of
Hazardous Materials (as defined below) on, from or under such properties or
facilities. Buyer has no Knowledge of any presence, disposals, releases or
threatened releases of Hazardous Materials on, from or under any of such
properties or facilities, which may have occurred prior to Buyer having taken
possession of any of such properties or facilities.
29
3.12.2 To
the
Knowledge of the Buyer, none of the properties or facilities of Buyer is in
violation of any federal, state or local law, ordinance, regulation or order
relating to industrial hygiene or to the environmental conditions on, under
or
about such properties or facilities, including, but not limited to, soil and
ground water condition. During the time that Buyer has owned or leased its
properties and facilities, neither Buyer, nor, to Buyer’s Knowledge, any third
party, has used, generated, manufactured or stored on, under or about such
properties or facilities or transported to or from such properties or facilities
any Hazardous Materials.
3.12.3 During
the time that Buyer has owned or leased their respective properties and
facilities, there has been no litigation brought or threatened against Buyer
by,
or any settlement reached by Buyer with, any party or parties alleging the
presence, disposal, release or threatened release of any Hazardous Materials
on,
from or under any of such properties or facilities.
3.13 Certain
Material Agreements.
Except
as set forth in the Buyer Disclosure Package or on the Buyer Disclosure
Schedule, the Buyer is not a party or subject to any oral or written material
contracts not entered into in the ordinary course of business, including, but
not limited to any:
(a) Contract
providing for payments by or to Buyer in an aggregate amount of $10,000 or
more;
(b) License
agreement as licensor or licensee (except for standard non-exclusive hardware
and software licenses granted to end-user customers in the ordinary course
of
business the form of which has been provided to Buyer’s counsel);
(c) Material
agreement for the lease of real or personal property;
(d) Joint
venture contract or arrangement or any other agreement that involves a sharing
of profits with other persons;
(e) Instrument
evidencing or related in any way to indebtedness for borrowed money by way
of
direct loan, sale of debt securities, purchase money obligation, conditional
sale, guarantee, or otherwise, except for trade indebtedness incurred in the
ordinary course of business, and except as disclosed in the Financial
Statements; or
(f) Contract
containing covenants purporting to limit Buyer’s freedom to compete in any line
of business in any geographic area.
All
agreements, contracts, plans, leases, instruments, arrangements, licenses and
commitments listed in the Buyer Disclosure Package or on Section 3.13 of the
Buyer Disclosure Schedule are valid and in full force and effect. Buyer is
not,
nor, to the Knowledge of Buyer, is any other party thereto, in breach or default
in any material respect under the terms of any such agreement, contract, plan,
lease, instrument, arrangement, license or commitment, which breach or default
may reasonably be expected to have a Material Adverse Effect on
Buyer.
30
4.
|
COMPANY
PRECLOSING COVENANTS
|
During
the period from the date of this Agreement until the Effective Time, Company
covenants and agrees as follows:
4.1 Advice
of Changes.
Company
will promptly advise Buyer in writing (a) of any event occurring subsequent
to
the date of this Agreement that would render any representation or warranty
of
Company contained in this Agreement, if made on or as of the date of such event
or the Closing Date, untrue or inaccurate in any material respect and (b) of
any
material adverse change in Company’s business, results of operations or
financial condition, other than as expressly contemplated by the Spinoff. To
ensure compliance with this Section 4.1,
Company
shall deliver to Buyer within fifteen (15) days after the end of each monthly
accounting period ending after the date of this Agreement and before the Closing
Date, an unaudited balance sheet and statement of operations, which financial
statements shall be prepared in the ordinary course of business, in accordance
with Company’s books and records and generally accepted accounting principles
and shall fairly present the financial position of Company as of their
respective dates and the results of Company’s operations for the periods then
ended.
4.2 Maintenance
of Business.
(a) Company
will use commercially reasonable efforts to carry on and preserve its business
and its relationships with customers, suppliers, employees and others in
substantially the same manner as it has prior to the date hereof, except in
connection with the Spinoff. If Company becomes aware of a material
deterioration in the relationship with any customer, supplier or key employee,
it will promptly bring such information to the attention of Buyer in writing
and, if requested by Buyer, will exert commercially reasonable efforts to
restore the relationship.
(b) Until
the
first to occur of the Closing or December 15, 0000, Xxxxxxxx
XxxXxxx Xxxxxxxx, X.X., Xxxxxxxx Xxx Xxxx Partners, LP and Xxxxxx Venture
Associates, LLC shall provide funding to the Company in such amounts as are
reasonably necessary to complete the Spinoff and pay the Company’s obligations
as they become due.
4.3 Conduct
of Business.
Except
in connection with the Spinoff, the Company will continue to conduct its
business and maintain its business relationships in the ordinary and usual
course. The Company will not, without the prior written consent of the President
or Chief Financial Officer of Buyer:
(a) borrow
any money, except for bridge loans from existing Company Securityholders to
fund
the Company’s needs for working capital and transaction expenses prior to the
Closing and which are cancelled or (with respect to transaction expenses in
accordance with Section 10.7 below), repaid upon Closing;
(b) except
as
described in Subsection (a) above, or except as otherwise expressly contemplated
in connection with the Spinoff, enter into any transaction not in the ordinary
course of business;
31
(c) except
as
described in Subsection (a) above, or except as otherwise expressly contemplated
in connection with the Spinoff, enter into any transaction with any of the
Company’s affiliates;
(d) encumber
or permit to be encumbered any of its assets except in the ordinary course
of
its business consistent with past practice and to an extent which is not
material;
(e) dispose
of any of its assets, including, but not limited to licenses;
(f) acquire
any material amount of assets (tangible or intangible);
(g) enter
into any lease or contract, or modification of an existing lease or contract,
for the purchase or sale of any property, real or personal, except as expressly
contemplated in connection with the Spinoff;
(h) fail
to
maintain its equipment and other assets in good working condition and repair
according to the standards it has maintained to the date of this Agreement,
subject only to ordinary wear and tear;
(i) pay
any
bonus, increased salary or special remuneration to any officer, employee or
consultant or enter into any new employment or consulting agreement with any
such person;
(j) change
accounting methods;
(k) declare,
set aside or pay any cash or stock dividend or other distribution in respect
of
capital stock, or redeem or otherwise acquire any of its capital stock, except
as expressly contemplated in connection with the Spinoff;
(l) amend
or
terminate any contract, agreement or license to which it is a party except
those
amended or terminated in the ordinary course of business, consistent with past
practice, and which are not material in amount, or as otherwise expressly
contemplated in connection with the Spinoff;
(m) lend
any
amount to any person or entity, other than (i) advances for travel and expenses
which are incurred in the ordinary course of business consistent with past
practice, not material in amount and documented by receipts for the claimed
amounts or (ii) any loans pursuant to the Company’s 401(k) plan;
(n) guarantee
or act as a surety for any obligation except for the endorsement of checks
and
other negotiable instruments in the ordinary course of business, consistent
with
past practice, which are not material in amount;
32
(o) waive
or
release any material right or claim except in the ordinary course of business,
consistent with past practice, or as otherwise expressly contemplated in
connection with the Spinoff;
(p) issue
or
sell any shares of its capital stock of any class (except upon the exercise
of
an option or warrant currently outstanding), or any other of its securities,
or
issue or create any warrants, obligations, subscriptions, options, convertible
securities, or other commitments to issue shares of capital stock (except as
described in Subsection (a) above), or except as set forth in Section
2.3.2
of the
Company Disclosure Schedule and Exhibit
B,
accelerate the vesting of any outstanding option or other security or change
the
terms of any outstanding option or other security;
(q) split
or
combine the outstanding shares of its capital stock of any class or enter into
any recapitalization affecting the number of outstanding shares of its capital
stock of any class or affecting any other of its securities;
(r) merge,
consolidate or reorganize with, or acquire any entity;
(s) amend
its
certificate of incorporation or bylaws;
(t) license
any of its technology or intellectual property except in the ordinary course
of
business consistent with past practice, or as otherwise expressly contemplated
in connection with the Spinoff;
(u) make
or
change any election, change an annual accounting period, adopt or change any
accounting method, file any amended tax return, enter into any closing
agreement, settle any tax claim or assessment relating to the Company or any
of
its subsidiaries, surrender any right to claim a refund of taxes, consent to
any
extension or waiver of the limitation period applicable to any tax claim or
assessment relating to the Company or any of its subsidiaries, or take any
other
similar action relating to the filing of any tax return or the payment of any
tax, if such election, adoption, change, amendment, agreement, settlement,
surrender, consent or other action (excluding the Spinoff) would have the effect
of materially increasing the tax liability of the Company or any of its
subsidiaries (other than Spinco) after the Closing Date or materially decreasing
any tax attribute of the Company or any of its subsidiaries (other than Spinco)
existing on the Closing Date.
(v) change
any insurance coverage or issue any certificates of insurance, except as
expressly contemplated in connection with the Spinoff; or
(w) agree
to
do any of the things described in the preceding clauses 4.3(a) through
4.3(v), except as otherwise expressly contemplated in connection with the
Spinoff.
4.4 Stockholder
Approval.
Company
will hold a special meeting of its stockholders or obtain a written consent
of a
majority of the stockholders in lieu thereof, at the earliest practicable date
to submit this Agreement, the Merger and related matters for the consideration
and approval of the Company stockholders, which approval will be recommended
by
Company’s board of directors and management, subject to the fiduciary
obligations of its directors and officers. Any such meeting, or consent
solicited, and any proxies solicited, will be in compliance with applicable
law.
33
4.5 Notice
Materials.
Company
will send to its stockholders in a timely manner, for the purpose of considering
and voting upon the Merger, the Notice Materials. Company will promptly provide
all information relating to its business or operations necessary for inclusion
in the Notice Materials to
satisfy all requirements of applicable state and federal securities laws.
Company shall be solely responsible for any statement, information or omission
in the Notice Materials relating
to it or its affiliates based upon written information furnished by it. Company
will not provide or publish to its stockholders any material concerning it
or
its affiliates that violates the Securities Act or Exchange Act with respect
to
the transactions contemplated hereby.
4.6 Regulatory
Approvals.
Company
will execute and file, or join in the execution and filing, of any application
or other document that may be necessary in order to obtain the authorization,
approval or consent of any governmental body, federal, state, local or foreign
which may be reasonably required, or which Buyer may reasonably request, in
connection with the consummation of the transactions contemplated by this
Agreement. Company will use commercially reasonable efforts to obtain all such
authorizations, approvals and consents.
4.7 Necessary
Consents.
Company
will use commercially reasonable efforts to obtain such written consents and
take such other actions as may be necessary or appropriate in addition to those
set forth in Section 2.6
and
Section 4.6
to allow
the consummation of the transactions contemplated hereby and to allow Buyer
to
carry on Company’s business after the Closing.
4.8 Litigation.
Company
will notify Buyer in writing promptly after learning of any material actions,
suits, proceedings or investigations by or before any court, board or
governmental agency, initiated by or against it, or known by it to be threatened
against it.
4.9 No
Other Negotiations.
From
the date hereof until the earlier of termination of this Agreement or
consummation of the Merger, Company will not, and will not authorize or permit
any officer, director, employee or affiliate of Company, or any other person,
on
its behalf to, directly or indirectly, solicit or encourage any offer from
any
party or, subject to the fiduciary obligations of its directors and officers
and
Section 8.1.5 below, consider any inquiries or proposals received from any
other
party, participate in any negotiations regarding, or furnish to any person
any
information with respect to, or otherwise cooperate with, facilitate or
encourage any effort or attempt by any person (other than Buyer), concerning
the
possible disposition of all or any substantial portion of Company’s business,
assets or capital stock by merger, sale or any other means (except with respect
to the Spinoff). Company will promptly notify Buyer orally and in writing of
any
such inquiries or proposals.
4.10 Access
to Information.
Until
the Closing, Company will allow Buyer and its agents reasonable access the
files, books, records and offices of Company, including, without limitation,
any
and all information relating to Company’s taxes, commitments, contracts, leases,
licenses, and real, personal and intangible property and financial condition.
Company will cause its accountants to cooperate with Buyer and its agents in
making available all financial information reasonably requested, including
without limitation the right to examine all working papers pertaining to all
financial statements prepared or audited by such accountants.
Company
will also make available to Buyer and its agents, all management and other
appropriate personnel during normal business hours, on reasonable prior
notice.
34
4.11 Satisfaction
of Conditions Precedent.
Company
will use commercially reasonable efforts to satisfy or cause to be satisfied
all
the conditions precedent which are set forth in Section 7,
and
Company will use commercially reasonable efforts to cause the transactions
contemplated by this Agreement to be consummated, and, without limiting the
generality of the foregoing, to obtain all consents and authorizations of third
parties and to make all filings with, and give all notices to, third parties
that may be necessary or reasonably required on its part in order to effect
the
transactions contemplated hereby.
4.12 Company
Affiliates Agreements.
To
ensure that the issuance of Buyer Common Stock in Merger 1 complies with the
Securities Act, concurrently with the execution of this Agreement Company will
deliver to Buyer a letter identifying all of the Company’s officers, directors
and holders of greater than 5% of any class of the Company’s outstanding equity
securities. Company will provide Buyer with all information and documents needed
to evaluate this list for compliance with securities laws. Company will cause
each of its affiliates to deliver to Buyer, on or prior to the Effective Time,
a
written agreement (the “Company
Affiliates Agreement”),
in
the form of Section 4.12
of the
Company Disclosure Schedule, providing that such person (a) has not made and
will not make any disposition of Company Stock in the 30 day period prior to
the
Effective Time, (b) will not offer to sell, sell or otherwise dispose of any
of
the Buyer Common Stock issued to such person in Merger 1 in violation of the
Securities Act and Rule 145 promulgated thereunder, as they may be amended
from
time to time.
4.13 Conversion
of Company Options and Company Warrants.
Company
agrees to solicit from the holders of Company Options and Company Warrants
consent to treat the Company Options and Company Warrants in accordance with
the
terms of this Agreement, including Section 1.11.
4.14 Exchange
of Convertible Debentures.
Company
agrees to solicit from the holders of Convertible Debentures consent to treat
the Convertible Debentures in accordance with the terms of this Agreement,
including Section 1.6.
4.15 Company
Dissenting Shares.
As
promptly as practicable after the date of any special meeting of its
stockholders or written consent of a majority of the stockholders in lieu
thereof, and prior to the Closing Date, Company shall furnish Buyer with the
name and address of each Company Dissenting Stockholder and the number of
Company Dissenting Shares owned by such Company Dissenting
Stockholder.
4.16 Blue
Sky Laws.
Company
shall use commercially reasonable efforts to assist Buyer to the extent
necessary to comply with the securities and Blue Sky laws of all jurisdictions
which are applicable in connection with the Merger.
35
4.17 Completion
of Spinoff.
Prior
to
the consummation of Merger 1, the Company shall use commercially reasonable
efforts to complete the contribution and assignment to a newly-formed Delaware
corporation (“Spinco”)
of all
the assets and the assumption by Spinco of all of the liabilities pertaining
to
the Company’s diagnostic technology and TRIPARTITE system as further described
in Schedule 4.17 in exchange for all of the stock of Spinco and then to
distribute of all the capital stock of Spinco to the Company Securityholders
(the “Spinoff”).
5.
|
BUYER
PRECLOSING COVENANTS
|
During
the period from the date of this Agreement until the Effective Time, Buyer
covenants and agrees as follows:
5.1 Advice
of Changes.
Buyer
will promptly advise Company in writing (a) of any event occurring subsequent
to
the date of this Agreement that would render any representation or warranty
of
Buyer contained in this Agreement, if made on or as of the date of such event
or
the Closing Date, untrue or inaccurate in any material respect and (b) of any
material adverse change in Buyer’s business, results of operations or financial
condition.
5.2 Regulatory
Approvals.
Buyer
will execute and file, or join in the execution and filing, of any application
or other document that may be necessary in order to obtain the authorization,
approval or consent of any governmental body, federal, state, local or foreign,
which may be reasonably required, or which Company may reasonably request,
in
connection with the consummation of the transactions contemplated by this
Agreement. Buyer will use commercially reasonable efforts to obtain all such
authorizations, approvals and consents.
5.3 Satisfaction
of Conditions Precedent.
Buyer
will use commercially reasonable efforts to satisfy or cause to be satisfied
all
the conditions precedent which are set forth in Section 6,
and
Buyer will use commercially reasonable efforts to cause the transactions
contemplated by this Agreement to be consummated, and, without limiting the
generality of the foregoing, to obtain all consents and authorizations of third
parties and to make all filings with, and give all notices to, third parties
that may be necessary or reasonably required on its part in order to effect
the
transactions contemplated hereby.
5.4 Blue
Sky Laws.
Buyer
shall take such steps as may be necessary to comply with the securities and
Blue
Sky laws of all jurisdictions which are applicable in connection with the
Merger.
6.
|
CONDITIONS
TO OBLIGATIONS OF COMPANY
|
Company’s
obligations hereunder are subject to the fulfillment or satisfaction, on and
as
of the Closing, of each of the conditions set forth below. Any one or more
of
the following conditions may be waived by Company, but only in a writing signed
by Company; provided, however, that if the Company proceeds with the Closing,
despite having Knowledge that any of the following conditions have not been
fulfilled, then it shall be deemed to have waived such condition.
36
6.1 Accuracy
of Representations and Warranties.
The
representations and warranties of Buyer set forth in Section 3
(as
qualified by the Buyer Schedule of Exceptions) shall be true and accurate in
every material respect on and as of the Closing with the same force and effect
as if they had been made at the Closing, except for changes contemplated by
this
Agreement and except for those representations and warranties that address
matters only as of a particular date (which shall remain true and correct as
of
such particular date), with the same force and effect as if they had been made
at the Closing, and
Company shall receive a certificate to such effect executed by Buyer’s President
and Chief Financial Officer.
6.2 Covenants.
Buyer
shall have performed and complied in all material respects with all of its
covenants contained in Section 5 on or before the Closing, and Company shall
receive a certificate to such effect signed by Buyer’s President and Chief
Financial Officer.
6.3 Absence
of Material Adverse Change.
There
shall not have been, in the reasonable judgment of the Board of Directors of
Company, any material adverse change in the business or financial condition
of
Buyer, and Company shall receive a certificate to such effect executed by
Buyer’s President and Chief Financial Officer, it being expressly acknowledged
that Buyer has historically incurred and continues to incur operating losses
in
the ordinary course of business. Operating losses at approximately such level,
together with all expenses incurred in connection with the transactions
contemplated by this Agreement, shall not constitute a material adverse change
in the business, assets (tangible or intangible), financial condition or
prospects of Buyer.
6.4 Compliance
with Law.
There
shall be no order, decree, or ruling by any court or governmental agency or
threat thereof, or any other fact or circumstance, which would prohibit or
render illegal the transactions contemplated by this Agreement.
6.5 Government
Consents.
There
shall have been obtained at or prior to the Closing Date such permits or
authorizations, and there shall have been taken such other action, as may be
required to consummate the Merger by any regulatory authority having
jurisdiction over the parties and the actions herein proposed to be taken,
including but not limited to requirements under applicable federal and state
securities laws.
6.6 Documents.
Company
shall have received all written consents, assignments, waivers, authorizations
or other certificates reasonably deemed necessary by Company’s legal counsel for
Company to consummate the transactions contemplated hereby.
6.7 Requisite
Approvals.
The
principal terms of this Agreement and the Certificates of Merger shall have
been
approved and adopted by Company stockholders, as required by applicable law
and
Company’s certificate of incorporation and bylaws.
6.8 Consent
of Holders of Company Options and Company Warrants.
The
acceleration of any Company Options and Company Warrants will have been
completed as set forth in Section 2.3.2
of the
Company Disclosure Schedule and Exhibit
B
and in
accordance with the terms of the Company Plans or with the consent or approval
of the holders of such securities.
37
6.9 Debt;
Convertible Debentures.
The
exchange of the Convertible Debentures will have been completed as set forth
in
this Agreement, Section 2.3.2
of the
Company Disclosure Schedule and Exhibit
B
and with
the consent or approval of the holders of such securities.
6.10 Consents.
Company
shall have received duly executed copies of all material third-party consents,
approvals, assignments, waivers, authorizations and other certificates
contemplated by this Agreement or the Company Disclosure Schedule in form and
substance reasonably satisfactory to Company including, but not limited to
the
Stakeholder Agreement, except for such consents and approvals as Buyer and
Company shall have agreed shall not be obtained, as contemplated by the Company
Disclosure Schedule.
6.11 Investment.
On the
Closing Date, Xxxxxxxx
MedTech Partners, L.P., Xxxxxxxx New York Partners, LP and Xxxxxx Venture
Associates, LLC
and
other investors shall invest an aggregate of at least $3,100,000 in NHI, on
terms mutually acceptable to NHI and such parties.
6.12 Stockholders
Agreement.
On
or
immediately prior to the Closing Date, Buyer, Company, the Company
Securityholders, Xxxx Xxxxxxxxxx and Xxxxxx Xxxxxxx shall enter into a
Stockholders Agreement in the form attached hereto as Exhibit
D
(the
“Stockholders
Agreement”),
which
Stockholders Agreement shall provide certain rights to the parties to that
agreement to appoint up to two individuals to serve on the Buyer’s Board of
Directors.
6.13 Registration
Rights Agreement.
On
or
immediately prior to the Closing Date, Buyer, Company and the Company
Securityholders shall enter into a Registration Rights Agreement in the form
attached hereto as Exhibit
E
(the
“Registration
Rights Agreement”),
which
Registration Rights Agreement shall also provide a two-year restriction on
the
sale of any of the Merger Consideration by the Company Securityholders except
as
otherwise provided therein.
6.14 Opinion
of Buyer’s Counsel.
Company
shall have received from counsel to Buyer, an opinion in form and substance
reasonably acceptable to the Company.
6.15 Satisfactory
Form of Legal and Accounting Matters.
The
form, scope and substance of all legal and accounting matters contemplated
hereby and all closing documents and other papers delivered hereunder shall
be
reasonably acceptable to the Company.
6.16 Employment
Agreements and Options.
The
Buyer will have entered into: (a) employment agreements with Xxxxxxx XxXxxxxx
as
full-time Chief Operating Officer and Xxxxxxx Xxxx in a part-time role as Vice
President of Product Development, and (b) a consulting agreement with Xx. Xxxxxx
X. Xxxxxx, in each case dated on or before the Closing Date (to become effective
on the Closing Date), in a form that is mutually acceptable to Buyer and the
individuals identified therein. All such agreements shall include grants of
options to purchase Common Stock of the Buyer as follows: (i) Xx. Xxxxxx X.
Xxxxxx shall be granted a 10-year option to acquire 500,000 shares of the
Buyer’s Common Stock, with an exercise price equal to the fair market value of
the Buyer’s Common Stock on the Effective Date (the “FMV”),
(ii)
Xxxxxxx XxXxxxxx shall be granted a 10-year option to acquire 300,000 shares
of
the Buyer’s Common Stock, with an exercise price equal to the FMV, and (iii)
Xxxxxxx Xxxx shall be granted a 10-year option to acquire such number of shares
of the Buyer’s Common Stock as is mutually acceptable to the Buyer and Xxxxxxx
Xxxx, with an exercise price equal to the FMV. All such options shall be on
such
other terms and conditions, including vesting, as is mutually acceptable to
Buyer and the individuals identified therein. Within 12 months following the
Closing, Buyer shall seek the approval of Buyer’s stockholders for the treatment
of such options as “incentive stock option” under Section 422 of the Code, and
if Buyer’s stockholders shall not so approve, such options shall be
non-qualified stock options, to the extent required by law. The employment
agreements for Xxxxxxx XxXxxxxx and Xxxxxxx Xxxx shall include provision for
employee benefits on terms mutually acceptable to Buyer and the individuals
identified therein.
38
6.17 Election
of Company Designees to the Board of Directors of Buyer.
The
Board of Directors of Buyer shall have taken appropriate action to elect Xxxxxxx
XxXxxxxx and Xx. Xxxxx Xxxxxxxx to the Board of Directors of Buyer, effective
upon the Effective Time.
7.
|
CONDITIONS
TO OBLIGATIONS OF BUYER
|
The
obligations of Buyer hereunder are subject to the fulfillment or satisfaction
on, and as of the Closing, of each of the conditions set forth below. Any one
or
more of the following conditions may be waived by Buyer, but only in a writing
signed by Buyer; provided, however, that if the Buyer proceeds with the Closing,
despite having Knowledge that any of the following conditions have not been
fulfilled, then it shall be deemed to have waived such condition.
7.1 Accuracy
of Representations and Warranties.
The
representations and warranties of Company set forth in Section 2
(as
qualified by the Company Disclosure Schedule) shall be true and accurate in
every material respect on and as of the Closing with the same force and effect
as if they had been made at the Closing, except for changes contemplated by
this
Agreement and except for those representations and warranties that address
matters only as of a particular date (which shall remain true and correct as
of
such particular date), with the same force and effect as if they had been made
at the Closing, and Buyer shall receive a certificate to such effect executed
by
Company’s Chief Executive Officer and Treasurer.
7.2 Covenants.
Company
shall have performed and complied in all material respects with all of its
covenants contained in Section 4
on or
before the Closing, and Buyer shall receive a certificate to such effect signed
by Company’s Chief Executive Officer and Treasurer.
7.3 Absence
of Material Adverse Change.
There
shall not have been, in the reasonable judgment of the Board of Directors of
Buyer, any material adverse change in the business, assets (tangible or
intangible), financial condition or prospects of Company and Buyer shall receive
a certificate to such effect executed by Company’s Chief Executive Officer and
Treasurer, it being expressly acknowledged that the Company has historically
incurred and continues to incur operating losses in the ordinary course of
business. Operating losses at approximately such level, together with all
expenses incurred in connection with the transactions contemplated by this
Agreement, shall not constitute a material adverse change in the business,
assets (tangible or intangible), financial condition or prospects of
Company.
39
7.4 Certificate
of Secretary.
Buyer
will have received from the corporate secretary of the Company a certificate
(i)
certifying the Company’s certificate of incorporation, (ii) certifying the
bylaws of the Company, (iii) certifying the resolutions of the board of
directors of Company approving the Merger and Merger Agreement, (iv) certifying
the resolutions of the stockholders of the Company approving the Merger and
Merger Agreement and (v) attesting to the incumbency of the officers of the
Company.
7.5 Compliance
with Law.
There
shall be no order, decree, or ruling by any court or governmental agency or
threat thereof, or any other fact or circumstance, which would prohibit or
render illegal the transactions contemplated by this Agreement.
7.6 Government
Consents.
There
shall have been obtained at or prior to the Closing Date such permits or
authorizations, and there shall have been taken such other action, as may be
required to consummate the Merger by any regulatory authority having
jurisdiction over the parties and the actions herein proposed to be taken,
including but not limited to requirements under applicable federal and state
securities laws.
7.7 Opinion
of Company’s Counsel.
Buyer
shall have received from counsel to Company, an opinion in form and substance
reasonably acceptable to the Buyer.
7.8 Consents.
Company
shall have received duly executed copies of all material third-party consents,
approvals, assignments, waivers, authorizations and other certificates
contemplated by this Agreement or the Company Disclosure Schedule in form and
substance reasonably satisfactory to Buyer including, but not limited to the
Stakeholder Agreement, except for such consents and approvals as Buyer and
Company shall have agreed shall not be obtained, as contemplated by the Company
Disclosure Schedule. In addition, Buyer shall have received duly executed copies
of all material third-party consents, approvals, assignments, waivers,
authorizations or other certificates set forth on Schedule
7.8
hereto.
7.9 No
Litigation.
No
litigation or proceeding shall be threatened or pending: (i) against the Company
or the Buyer for the purpose or with the probable effect of enjoining or
preventing the consummation of any of the transactions contemplated by this
Agreement, or (ii) against the Company which could be reasonably expected to
have a Material Adverse Effect on the present or future assets (tangible or
intangible), operations, financial condition or prospects of
Company.
7.10 Requisite
Approvals.
The
principal terms of this Agreement and the Certificates of Merger shall have
been
approved and adopted by Company stockholders, as required by applicable law
and
Company’s certificate of incorporation and bylaws, and by Company’s Board of
Directors, and consented to by the holders of Convertible Debentures, Company
Warrants and Company Options in the form of the Stakeholder
Agreement.
7.11 Consent
of Holders of Company Options and Company Warrants.
The
acceleration of any Company Options and Company Warrants will have been
completed as set forth in Section 2.3.2
of the
Company Disclosure Schedule and Exhibit
B
and in
accordance with the terms of the Company Plans or with the consent or approval
of the holders of such securities.
40
7.12 Debt;
Convertible Debentures.
The
exchange of the Convertible Debentures will have been completed as set forth
in
this Agreement, Section 2.3.2
of the
Company Disclosure Schedule and Exhibit
B
and with
the consent or approval of the holders of such securities. The Company shall
have no remaining debt for borrowed money, except for obligations to repay
Xxxxxxxx
MedTech Partners, L.P., Xxxxxxxx New York Partners LP, and Xxxxxx Venture
Associates, LLC
for
advances made by them to pay the Company’s legal fees in connection with the
transactions contemplated by this Agreement, in accordance with Section 10.7
below. Including all Authorized Post-Closing Debt (as hereinafter defined),
the
Company’s other debt shall not exceed $200,000. As used herein the term
“Authorized
Post-Closing Debt”
shall
mean: (i) any payables then due on account of the Company’s written employment,
license and sponsored research agreements, and (ii) any amounts then due for
prosecution or maintenance fees on account of the Company’s Intellectual
Property.
7.13 Employment
Agreements.
The
Buyer
will have entered into: (a) employment agreements with Xxxxxxx XxXxxxxx as
full-time Chief Operating Officer and Xxxxxxx Xxxx in a part-time role as Vice
President of Product Development, and (b) a consulting agreement with Xx. Xxxxxx
X. Xxxxxx, in each case dated on or before the Closing Date (to become effective
on the Closing Date), in a form that is mutually acceptable to Buyer and the
individuals identified therein.
7.14 Dissenting
Shares.
Holders
of: (i) at least 90% of the total number of shares of Company Stock outstanding
immediately prior to the Effective Time shall have consented to the Merger
and
(ii) not more than 5% of the total number of shares of Company Stock outstanding
immediately prior to the Effective Time shall have objected to the Merger in
writing or exercised their dissenter’s rights under Delaware Law.
7.15 Accredited
Investor Questionnaire.
No more
than thirty-five (35) Company Securityholders shall, in the aggregate, have
failed to meet the definition of “accredited investor” within the meaning of
Regulation D promulgated under the Securities Act, which accreditation shall
have been determined by the delivery to the Company of an “accredited investor”
questionnaire prior to the Closing. For purposes of determining the status
of a
Company Securityholder under this
Section
7.15,
the
failure to deliver a completed “accredited investor” questionnaire shall be
deemed the failure of such Securityholder to meet the accreditation requirements
under Regulation D promulgated under the Securities Act.
7.16 Investment.
On the
Closing Date, Xxxxxxxx
MedTech Partners, L.P., Xxxxxxxx New York Partners, LP and Xxxxxx Venture
Associates, LLC
and
other investors shall invest an aggregate of at least $3,100,000 in NHI, on
terms mutually acceptable to NHI and such parties.
7.17 Registration
Rights Agreement.
On or
immediately prior to the Closing Date, the Buyer, Company and the
Securityholders shall enter into the Registration Rights Agreement.
7.18 Stockholders
Agreement.
On or
immediately prior to the Closing Date, the Buyer, Company and the
Securityholders shall enter into the Stockholders Agreement.
41
7.19 Affiliates
Agreements.
Company
shall have delivered to Buyer the letter required by Section 4.11
naming
all persons who are “affiliates” of Company for purposes of Rule 145 under the
Securities Act, and each such person, if any, shall have executed and delivered
a Company Affiliates Agreement to Buyer.
7.20 Termination
of Rights.
Except
as otherwise provided in Section 6.13, any registration rights, rights of
refusal, rights to any liquidation preference, or redemption rights of any
Company Securityholders shall have been terminated or waived as of the
Closing.
7.21 Resignation
of Directors and Officers.
The
directors and officers of Company in office immediately prior to the Effective
Time of the Merger shall have resigned as directors and officers of the
Surviving Entity effective as of the effectiveness of Merger 2.
7.22 Completion
of Spinoff.
The
Company shall have completed the Spinoff.
7.23 Escrow
Agreement.
On or
immediately prior to the Closing Date, the Buyer, the Company Securityholders
and Empire Stock Transfer, as escrow agent, shall enter into the Escrow
Agreement (as defined in Section 9.9 below).
7.24 Satisfactory
Form of Legal and Accounting Matters.
The
form, scope and substance of all legal and accounting matters contemplated
hereby and all closing documents and other papers delivered hereunder
(including, but not limited to the audited Financial Statements) shall be
acceptable to Buyer.
7.25 FIRPTA
Affidavit.
The
Company shall deliver to the Buyer an affidavit, under penalties of perjury,
stating that the Company is not and has not been a United States real property
holding corporation, dated as of the Closing Date and in form and substance
required under Treasury Regulation Section 1.897-2(h) so that Buyer is exempt
from withholding any part of the Merger Consideration. Buyer shall prepare
and
deliver a form of such affidavit to the Company no later than five (5) days
prior to the Closing Date.
8.
|
TERMINATION
OF AGREEMENT
|
8.1 Prior
to Closing.
8.1.1 This
Agreement may be terminated at any time prior to the Closing by the mutual
written consent of each of the parties hereto.
8.1.2 Unless
otherwise agreed by the parties hereto, this Agreement will be terminated if
all
conditions to the Closing have not been satisfied or waived on or before
December 15, 2006; provided, however,
that
the right to terminate this Agreement pursuant to this Section 8.1.2
shall
not be available to any party whose failure to perform in any material respect
any of its obligations or covenants under this Agreement results in the failure
of any condition set forth in Section 6
or
Section 7
or if
the failure of such condition results from facts or circumstances that
constitute a material breach of a representation or warranty or covenant made
under this Agreement by such party.
42
8.1.3 Either
Buyer or Company, by giving written notice to the other, may terminate this
Agreement if a court of competent jurisdiction or other Governmental Authority
shall have issued a nonappealable final order, decree or ruling or taken any
other action, in each case having the effect of permanently restraining,
enjoining or otherwise prohibiting the Merger.
8.1.4 This
Agreement may be terminated at any time prior to the Effective Time by Buyer
(at
any time prior to the adoption and approval of this Agreement and the Merger
by
the required vote of the Company stockholders) if a Triggering Event (as defined
below) shall have occurred.
8.1.5 Superior
Offer.
(a) Nothing
in this Agreement shall prevent the Company board of directors from withholding,
withdrawing, amending or modifying its unanimous recommendation in favor of
the
Merger if (i) a Superior Offer (as defined below) is made to Company and is
not
withdrawn, (ii) Company shall have provided written notice to Buyer (a
“Notice
of Superior Offer”)
advising Buyer that Company has received a Superior Offer, specifying all of
the
material terms and conditions of such Superior Offer and identifying the person
or entity making such Superior Offer, (iii) Buyer shall not have, within five
(5) business days of Buyer’s receipt of the Notice of Superior Offer, made an
offer in writing that the Company board of directors by a majority vote
determines in its good faith judgment to be at least as favorable to the Company
stockholders as such Superior Offer (it being agreed that the Company board
of
directors shall convene a meeting to consider any such offer by Buyer as soon
as
reasonably practicable following the receipt thereof), (iv) the Company board
of
directors concludes in good faith, after consultation with its outside counsel,
that, in light of such Superior Offer, the withholding, withdrawal, amendment
or
modification of such recommendation is required in order for the Company board
of directors to comply with its fiduciary obligations to the Company
stockholders under applicable law and (v) Company shall not have violated any
of
the restrictions set forth in this Section 8.1.5.
Company
shall provide Buyer with at least two (2) business days prior notice (or such
lesser prior notice as provided to the members of Company’s board of directors
but in no event less than twenty-four hours) of any meeting of Company’s board
of directors at which Company’s board of directors is reasonably expected to
consider any Acquisition Proposal (as defined below) to determine whether such
Acquisition Proposal is a Superior Offer. In the event Company, after complying
with the requirements of this Section 8.1.5 (a)
determines to pursue a Superior Offer (as defined herein), Company shall have
the right to terminate this Agreement subject to the provisions in Section
8.3.
43
(b) From
and
after the date of this Agreement until the Effective Time or termination of
this
Agreement pursuant to Section 8.1,
Company
will not, nor will it authorize or permit any of its respective officers,
directors, affiliates or employees or any investment banker, attorney or other
advisor or representative retained by it to, directly or indirectly, (i)
solicit, initiate, encourage or induce the making, submission or announcement
of
any Acquisition Proposal, (ii) participate in any discussions or negotiations
regarding, or furnish to any person any non-public information with respect
to,
or take any other action to facilitate any inquiries or the making of any
proposal that constitutes or may reasonably be expected to lead to, any
Acquisition Proposal, (iii) engage in discussions with any person with respect
to any Acquisition Proposal, except as to the existence of these provisions,
(iv) approve, endorse or recommend any Acquisition Proposal or (v) enter into
any letter of intent or similar document or any contract, agreement or
commitment contemplating or otherwise relating to any Acquisition Proposal;
provided,
however,
that
prior to the Effective Time, this Section (a)
shall
not prohibit the Company from furnishing information regarding Company to,
or
entering into discussions with, any person or group who has submitted (and
not
withdrawn) to the Company an unsolicited, written, bona fide Acquisition
Proposal that the Company board of directors in good faith concludes may
constitute a Superior Offer if (1) neither Company nor any representative of
Company shall have violated any of the restrictions set forth in this Section
(a),
(2) the
Company board of directors concludes in good faith, after consultation with
its
outside legal counsel, that such action is required in order for the Company
board of directors to comply with its fiduciary obligations to the Company
stockholders under applicable law, (3) prior to furnishing any such nonpublic
information to, or entering into any such discussions with, such person or
group, the Company gives Buyer written notice of the identity of such person
or
group and all of the material terms and conditions of such Acquisition Proposal
and of the Company’s intention to furnish nonpublic information to, or enter
into discussions with, such person or group, and the Company receives from
such
person or group an executed confidentiality agreement, containing terms at
least
as restrictive with regard to the Company’s confidential information as the
Confidentiality Agreement executed between the Company and Buyer prior to the
execution of this Agreement, (4) Company gives Buyer at least two (2) business
days advance notice of its intent to furnish such nonpublic information or
enter
into such discussions, and (5) contemporaneously with furnishing any such
nonpublic information to such person or group, Company furnishes such nonpublic
information to Buyer (to the extent such nonpublic information has not been
previously furnished by Company to Buyer). Company will immediately cease any
and all existing activities, discussions or negotiations with any parties
conducted heretofore with respect to any Acquisition Proposal. Without limiting
the foregoing, it is understood that any violation of the restrictions set
forth
in the preceding two sentences by any officer, director or employee of the
Company or any investment banker, attorney or other advisor or representative
of
the Company shall be deemed to be a breach of this Section 8.1.5(b)
by
Company.
In
addition to the obligations of the Company set forth in this Section
8.1.5(b),
Company
as promptly as practicable shall advise Buyer orally and in writing of any
request for information which Company reasonably believes would lead to an
Acquisition Proposal or of any Acquisition Proposal, or any inquiry with respect
to or which Company reasonably should believe would lead to any Acquisition
Proposal, the material terms and conditions of such request, Acquisition
Proposal or inquiry, and the identity of the person or group making any such
request, Acquisition Proposal or inquiry. Company will keep Buyer informed
as
promptly as practicable in all material respects of the status and details
(including material amendments or proposed amendments) of any such request,
Acquisition Proposal or inquiry.
For
the
purposes of this Agreement, a “Triggering
Event”
shall
be deemed to have occurred if: (i) Company board of directors or any committee
thereof shall for any reason have withdrawn or shall have amended or modified
in
a manner adverse to Buyer its recommendation in favor of the adoption and
approval of the Agreement or the approval of the Merger; (ii) the Company shall
have failed to include in its communications with the Company stockholders
the
recommendation of the Company board of directors in favor of the adoption and
approval of the Agreement and the approval of the Merger; (iii) the Company
board of directors fails to reaffirm its recommendation in favor of the adoption
and approval of the Agreement and the approval of the Merger within ten (10)
business days after Buyer requests in writing that such recommendation be
reaffirmed at any time following the public announcement of an Acquisition
Proposal (as defined below); (iv) the Company board of directors or any
committee thereof shall have approved or publicly recommended any Acquisition
Proposal; or (v) the Company shall have entered into any letter of intent or
similar document or any agreement, contract or commitment accepting any
Acquisition Proposal.
44
For
purposes of this Agreement, “Acquisition
Proposal”
shall
mean any offer or proposal from a third party relating to: (A) any acquisition
or purchase from Company by any person or “group” (as defined under Section
13(d) of the Exchange Act and the rules and regulations thereunder) of more
than
a 20% interest in the total outstanding voting securities of the Company; (B)
any sale, lease (other than in the ordinary course of business), exchange,
transfer, license (other than in the ordinary course of business), acquisition,
or disposition of more than 50% of the assets of the Company; or (C) any
liquidation or dissolution of the Company.
For
purposes of this Agreement “Superior
Offer”
shall
mean an unsolicited, bona fide written Acquisition Proposal on terms that the
Company board of directors determines, in its reasonable judgment, to be more
favorable to the Company Securityholders than the terms of the Merger; provided,
however, that any such offer shall not be deemed to be a “Superior Offer” if any
financing required to consummate the transaction contemplated by such offer
is
not likely in the reasonable judgment of the Company’s board of directors to be
obtained by such third party on a timely basis.
8.2 At
the Closing.
At the
Closing, this Agreement may be terminated and abandoned:
8.2.1 By
Buyer
if any of the conditions precedent to Buyer’s obligations set forth in Section
7
above
have not been fulfilled or waived at and as of the Closing; or
8.2.2 By
Company if any of the conditions precedent to Company’s obligations set forth in
Section 6
above
have not been fulfilled or waived at and as of the Closing.
Any
termination of this Agreement under this Section 8
will be
effective by the delivery of notice of the terminating party to the other party
hereto.
8.3 Company
Payments.
In the
event that this Agreement is terminated by Buyer or the Company, as applicable,
pursuant to Section 8.1.4 or Section 8.1.5,
Company
shall promptly, but in no event later than two days after the date of such
termination, pay Buyer a fee equal to $600,000 in immediately available funds
(the “Termination
Fee”).
Company acknowledges that the agreements contained in this Section 8.3 are
an
integral part of the transactions contemplated by this Agreement, and that,
without these agreements, Buyer would not enter into this Agreement.
Accordingly, if the Company fails to pay in a timely manner the amounts due
pursuant to this Section 8.3, and, in order to obtain such payment, Buyer makes
a claim that results in a final, non-appealable judgment against Company for
the
amounts set forth in this Section 8.3, the Company shall pay to Buyer its
reasonable costs and expenses (including reasonable attorneys’ fees and
expenses) in connection with such suit, together with interest on the amounts
set forth in this Section 8.3 at the prime rate in effect on the date such
payment was required to be made (as published in the Wall Street Journal).
Payment of the fees described in this Section 8.3 shall not be in lieu of
damages incurred in the event of breach of this Agreement.
45
9.
|
SURVIVAL
OF REPRESENTATIONS, INDEMNIFICATION AND REMEDIES, CONTINUING
COVENANTS
|
9.1 Survival
of Representations.
Except
for covenants that by their terms survive for a longer period, all
representations, warranties, covenants and indemnities of the parties contained
in this Agreement will remain operative and in full force and effect, regardless
of any investigation made by or on behalf of the other parties to this
Agreement, until the earlier of the termination of this Agreement or eighteen
months after the Effective Date (the “Survival
Period”).
9.2 Indemnification
of Buyer.
Subject
to the limitations set forth in this Section 9,
Company
Securityholders agree to indemnify and hold harmless Buyer and its officers,
directors, agents and employees, and each person or entity, if any, who controls
or may control Buyer within the meaning of the Securities Act from and against
any and all claims, demands, actions, causes of actions, losses, costs, damages,
liabilities and expenses including, without limitation, reasonable legal fees
(hereinafter referred to as “Damages”):
9.2.1 arising
out of any misrepresentation or breach of or default of the representations,
warranties and covenants given or made by Company in this Agreement or any
certificate, document or instrument delivered by or on behalf of Company
pursuant hereto, provided, however that for purposes of this Section 9.2.1
only,
the Company shall only be deemed to have breached a representation, warranty
or
covenant that contains a limitation based upon the absence of a Material Adverse
Effect, or any other materiality qualification, if such breach results in more
than $3,500 in Damages to the Buyer; or
9.2.2 arising
out of any liabilities or obligations of the Company intended to be assumed
by
Spinco in connection with the Spinoff, as set forth on Schedule
4.17;
9.2.3 for
any
income taxes (including alternative minimum taxes) of the Company for the period
ending on the Closing Date;
9.2.4 for
(a)
any taxes of the Company for the period ending on the Closing Date other than
those specified in Section 9.2.3, (b) any taxes of any member of an affiliated,
consolidated, combined or unitary group of which the Company or any of its
subsidiaries (or any predecessor of the foregoing) was a member on or before
the
Closing Date, including pursuant to Treasury Regulation Section 1.1502-6 or
any
analogous or similar state, local or foreign law or regulation and (c) any
and
all taxes of any other person imposed on the Company or its subsidiaries as
a
transferee or successor by contract or pursuant to any law, rule or regulations
which relate to an event or transaction occurring before the Closing, but only
to the extent that the taxes specified in clauses (a), (b) and (c) of this
Section 9.2.4 exceed the reserve for tax liability (rather than any reserve
for
deferred taxes established to reflect timing differences between book and tax
income) set forth on the face of the Company Balance Sheet (rather than in
any
notes thereto); or
46
9.2.5 resulting
from any failure of the Stockholders to have good, valid and marketable title
to
the issued and outstanding Company Stock held by them, free and clear of all
liens, claims, pledges, options, adverse claims, assessments or charges of
any
nature whatsoever, or to have full right, capacity and authority to vote such
Company Stock in favor of the Merger and the other transactions contemplated
by
the Merger Agreement.
The
foregoing are collectively referred to as the “Buyer
Indemnity Claims.”
9.3 Indemnification
of Company Securityholders.
Subject
to the limitations set forth in this Section 9,
Buyer
and Buyer Sub agree to jointly and severally indemnify and hold harmless the
Company Securityholders and their officers, directors, agents and employees,
from and against any and all Damages arising out of any misrepresentation or
breach of or default in connection with any of the representations, warranties
and covenants given or made by Buyer or Buyer Sub in this Agreement or any
certificate, document or instrument delivered by or on behalf of Buyer or Buyer
Sub pursuant hereto, in each case without giving effect to any limitation in
such representation, warranty or covenant based upon the absence of a Material
Adverse Effect, or any other materiality qualification.
The
foregoing are collectively referred to as the “Company
Indemnity Claims.”
The
Company Indemnity Claims together with Buyer Indemnity Claims are collectively
referred to as the “Indemnity
Claims.”
9.4 General
Notice and Procedural Requirements for Indemnity Claims.
Notwithstanding the foregoing, the party having the indemnity obligation under
this Section 9
(the
“Indemnifying
Party”),
shall
be obligated to indemnify and hold harmless the party entitled to indemnity
under this Section 9
(the
“Indemnified
Party”),
only
with respect to any Indemnity Claims of which the Indemnified Party notifies
with specificity the Indemnifying Party in accordance with Section 10.9
of this
Agreement and, if applicable, within the following time period: (i) with regard
to any representation or warranty under this Agreement, prior to the end of
the
Survival Period of such representation or warranty; or (ii) with regard to
any
covenant under this Agreement which by its terms expires, prior to the end
of
the survival period relating to such covenant.
9.5 Notice
and Procedural Requirements for Third Party Claims.
If a
complaint, claim or legal action is brought by a third party (a “Third
Party Claim”)
as to
which an Indemnified Party is entitled to indemnification, the Indemnified
Party
shall give written notice of such Third Party Claim to the Indemnifying Party
in
accordance with Section 10.9
of this
Agreement promptly after the Indemnified Party receives notice thereof, which
notice shall include a copy of any letter, complaint or similar writing received
by the Indemnified Party; provided however, that any failure to provide or
delay
in providing such information shall not constitute a bar or defense to
indemnification except as provided in Section 9.4(i) above or to the extent
the
Indemnifying Party has been prejudiced thereby.
47
The
Indemnifying Party shall have the right to assume the defense of such Third
Party Claim with counsel reasonably satisfactory to the Indemnified Party.
After
notice from the Indemnifying Party to the Indemnified Party of the Indemnifying
Party’s election so to assume the defense of such Third Party Claim, the
Indemnifying Party shall not be liable to the Indemnified Party for any legal
or
other expenses subsequently incurred by the Indemnified Party in connection
with
the defense of such Third Party Claim except as hereinafter provided. If the
Indemnifying Party elects to assume such defense and select counsel, the
Indemnified Party may participate in such defense through its own separate
counsel, but the fees and expenses of such counsel shall be borne by the
Indemnified Party unless: (i) otherwise specifically agreed by the Indemnifying
Party, or (ii) counsel selected by the Indemnifying Party determines that
because of a conflict of interest between the Indemnifying Party and the
Indemnified Party such counsel for the Indemnifying Party cannot adequately
represent both parties in conducting the defense of such action. In the event
the Indemnified Party maintains separate counsel because counsel selected by
the
Indemnifying Party has determined that such counsel cannot adequately represent
both parties because of a conflict of interest between the Indemnifying Party
and the Indemnified Party, then the Indemnifying Party shall not have the right
to direct the defense of such Third Party Claim on behalf of the Indemnified
Party.
The
failure of the Indemnifying Party to notify an Indemnified Party of its election
to defend such Third Party Claim within thirty (30) days after notice thereof
was given to the Indemnifying Party shall be deemed a waiver by the Indemnifying
Party of its rights to defend such Third Party Claim.
If
the
Indemnifying Party assumes the defense of a Third Party Claim, the obligations
of the Indemnifying Party shall include taking all steps reasonably necessary
in
the defense of such Third Party Claim and holding the Indemnified Party harmless
from and against any and all Damages caused or arising out of any settlement
negotiated by the Indemnifying Party and approved by the Indemnified Party
(not
to be unreasonably withheld or delayed) or any judgment in connection with
the
claim or litigation.
If
the
Indemnifying Party does not assume the defense of such Third Party Claim in
accordance with this Section, the Indemnified Party may defend against such
claim or litigation in such manner as it deems appropriate; provided, however,
that the Indemnified Party may not settle such Third Party Claim without the
prior written consent of the Indemnifying Party; provided that the Indemnifying
Party may not withhold such consent unless it has provided security of a type
and in an amount reasonably acceptable to the Indemnified Party for the payment
of its indemnification obligations with respect to such Third Party Claim.
The
Indemnifying Party shall promptly reimburse the Indemnified Party for the amount
of Damages caused or arising out of any judgment rendered with respect to such
Third Party Claim, and for all costs and expenses incurred by the Indemnified
Party in the defense of such claim.
The
Indemnifying Party may settle any Third Party Claim in its sole discretion
without the prior written consent of the Indemnified Party, provided that such
settlement involves only the payment of cash by the Indemnifying Party to the
claimant and does not impose any other liability or obligation on the
Indemnified Party.
48
9.6 Notice
and Procedural Requirements for Direct Claims.
Any
claim for indemnification by an Indemnified Party on account of Damages which
do
not result from a Third Party Claim (a “Direct
Claim”)
shall be
asserted by giving the Indemnifying Party reasonably prompt notice thereof
in
accordance with Section 10.9
of this
Agreement; provided, however, that any failure to provide, or delay in
providing, such notification shall not constitute a bar or defense to
indemnification except as provided in Section 9.4(i) above or to the extent
the
Indemnifying Party has been prejudiced thereby. After receiving notice of a
Direct Claim, the Indemnifying Party will have a period of thirty (30) days
within which to respond in writing to such Direct Claim. If the Indemnifying
Party rejects such claim or does not respond within such thirty (30) day period
(in which case the Indemnifying Party will be deemed to have rejected such
claim), the Indemnified Party will be free to pursue such remedies as may be
available to the Indemnified Party on the terms and subject to the provisions
of
this Section 9.
9.7 Maximum
Liability.
Notwithstanding anything to the contrary in this Agreement, in no event will
the
Company Securityholders aggregate indemnity obligations under this Section
9
exceed
20% of the Merger Consideration (“Aggregate
Company Limit”),
except for any claims of indemnity based on actual fraud by the Company, for
which the Buyer may seek rescission of the transactions contemplated by this
Agreement. In addition, in no event will any Company Security Holder’s
individual aggregate indemnity obligations under this Section 9
exceed
his, her or its pro rata share of the Aggregate Company Limit. In no event
will
the Buyer’s indemnity obligations under this Section 9
exceed
20% of the Merger Consideration, except for any claims of indemnity based on
actual fraud, for which the Company Securityholders may seek rescission of
the
transactions contemplated by this Agreement.
9.8 Basket.
Notwithstanding anything to the contrary in this Agreement, in no event shall
an
Indemnifying Party have any liability for an indemnity obligation under this
Section 9
unless
and until the Damages relating to the party’s Indemnity Claims exceed $250,000
in the aggregate. From and after the time the aggregate Damages for an
Indemnified Party’s Indemnity Claims exceed $250,000, the limitation set forth
in this Section 9.8
shall be
of no further force and effect and the Indemnifying Party shall be liable for
the entire amount of the Damages, subject to the liability limitations of
Section 9.7.
9.9 Source
of and Method of Recovery.
(a) Recovery
pursuant to the indemnification provisions contained in this Agreement shall
be
solely and exclusively the cancellation of the Buyer Common Stock and Buyer
Warrants issued as Merger Consideration or the issuance of additional Buyer
Common Stock and Buyer Warrants, except in the case of an allegation of fraud;
provided, however that any Indemnifying Party may elect, in its sole discretion,
to satisfy any indemnity obligation in cash. If the Buyer becomes ultimately
entitled to cancel Buyer Common Stock and Buyer Warrants issued as Merger
Consideration pursuant to this Section 9, Buyer shall provide the Representative
with at least 30 days prior written notice so that the Representative may
determine whether any Stakeholders wish to satisfy their indemnity obligation
in
cash.
(b) In
order
to facilitate any required cancellation of the Buyer Common Stock and Buyer
Warrants as provided herein, (a) the Buyer Warrants shall provide that the
Buyer
may offset and cancel up to 20% of the Shares of Buyer Common Stock covered
thereby if the Company Securityholders are required to indemnify the Buyer,
in
accordance with and subject to the terms of this Section 9, and (b) certificates
representing 20% of the Buyer Common Stock, together with appropriate stock
powers, shall be placed in escrow with Empire Stock Transfer, as escrow agent,
pursuant to the terms of an Escrow Agreement in the form attached hereto as
Exhibit
F.
49
(c) Subject
to the provisions of Section 9.9(a) above, if the Buyer becomes ultimately
entitled to cancel Buyer Common Stock and Buyer Warrants issued as Merger
Consideration pursuant to this Section 9, (i) one-third of the indemnification
amount shall be satisfied by the cancellation of Buyer Common Stock, pro rata
among the Stakeholders according to the number of shares of Buyer Common Stock
held by each such Stakeholder, as compared to the total number of shares of
Buyer Common Stock held by all Stakeholders; (ii) one-third of the
indemnification amount shall be satisfied by the cancellation of Buyer Warrants
having a $13 per share exercise price (“$13
Warrants”),
pro
rata among the Stakeholders according to the number of $13 Warrants held by
each
such Stakeholder, as compared to the total number of $13 Warrants held by all
Stakeholders; and (iii) one-third of the indemnification amount shall be
satisfied by the cancellation of Buyer Warrants having a $18 per share exercise
price (“$18
Warrants”),
pro
rata among the Stakeholders according to the number of $18 Warrants held by
each
such Stakeholder, as compared to the total number of $18 Warrants held by all
Stakeholders. If, by virtue of the application of the foregoing formula, a
Stakeholder’s holdings of $13 Warrants and/or $18 Warrants is exhausted and an
indemnification amount remains, the balance of the indemnification amount shall
be satisfied by the cancellation of Buyer Common Stock. It is expressly
acknowledged and agreed that no Buyer Options shall be cancelled as a result
of
any indemnity obligations.
(d) If
the
Buyer becomes ultimately obligated to issue Buyer Common Stock and Buyer
Warrants as additional Merger Consideration pursuant to this Section 9, (i)
one-third of the indemnification amount shall be satisfied by the issuance
of
Buyer Common Stock, (ii) one-third of the indemnification amount shall be
satisfied by the issuance of $13 Warrants, and (iii) one-third of the
indemnification amount shall be satisfied by the cancellation of $18 Warrants.
It is expressly acknowledged and agreed that no Buyer Options shall be issued
as
a result of any indemnity obligations.
(e) Notwithstanding
the market value of the Buyer Common Stock and Buyer Warrants, for purposes
of
calculating the indemnity obligations, the value of Buyer Common Stock and
Buyer
Warrants shall be deemed to be the amounts set forth on Exhibit
G
hereto.
9.10 Exclusivity.
The
parties agree that the provisions of this Section 9 shall constitute their
exclusive remedy with respect to any damage, loss, cost, expense or liability
in
connection with any term or provision of this Agreement or
any
certificate, document or instrument delivered by or on behalf of any of the
parties hereto;
provided, however, that if any of the provisions of this Agreement are not
performed in accordance with their terms or are otherwise breached, the parties
hereto shall be entitled to seek specific performance remedies.
50
10.
|
MISCELLANEOUS
|
10.1 Governing
Law.
The
internal laws of the State of Delaware (irrespective of its choice of law
principles) will govern the validity of this Agreement, the construction of
its
terms, and the interpretation and enforcement of the rights and duties of the
parties hereto.
10.2 Assignment;
Binding Upon Successors and Assigns.
None of
the parties to this Agreement may assign any of its respective rights or
obligations hereunder without the prior written consent of the other parties
hereto. This Agreement will be binding upon and inure to the benefit of the
parties hereto and their respective successors and permitted
assigns.
10.3 Severability.
If any
provision of this Agreement, or the application thereof, will for any reason
and
to any extent be invalid or unenforceable, the remainder of this Agreement
and
application of such provision to other persons or circumstances will be
interpreted so as reasonably to effect the intent of the parties hereto. The
parties further agree to replace such void or unenforceable provision of this
Agreement with a valid and enforceable provision that will achieve, to the
extent possible, the economic, business and other purposes of the void or
unenforceable provision.
10.4 Counterparts.
This
Agreement may be executed in any number of counterparts, each of which will
be
an original as regards any party whose signature appears thereon and all of
which together will constitute one and the same instrument. This Agreement
will
become binding when one or more counterparts hereof, individually or taken
together, will bear the signatures of both parties reflected hereon as
signatories.
10.5 Amendment
and Waivers.
Any
term or provision of this Agreement may be amended, and the observance of any
term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively) only by a writing signed
by
the party to be bound thereby. The waiver by a party of any breach hereof or
default in the performance hereof will not be deemed to constitute a waiver
of
any other default or any succeeding breach or default. The Agreement may be
amended by the parties hereto at any time before or after approval of the
Company stockholders, but, after such approval, no amendment will be made which
by applicable law requires the further approval of the Company stockholders
without obtaining such further approval.
10.6 No
Waiver.
The
failure of any party to enforce any of the provisions hereof will not be
construed to be a waiver of the right of such party thereafter to enforce such
provisions.
10.7 Expenses.
Each
party will bear its respective expenses and legal fees incurred with respect
to
this Agreement, and the transactions contemplated hereby, provided,
however,
that
Buyer shall (i) pay the reasonable fees and expenses of legal counsel to Company
for those fees and expenses incurred in connection with the Merger and the
Private Placement at the Closing (not to exceed $250,000); (ii) pay $10,123
towards the cost of purchasing a “tail” to the Company’s existing Directors,
Officers and Organization Liability Insurance Policy;
(iii)
pay $5,000 towards the cost of retaining a Purchaser Representative (as defined
in Rule 501 under Regulation D promulgated under the Securities Act) on behalf
of certain of the Stakeholders; and (iv) pay that portion of the
fees
and expenses incurred by Company in the preparation of the audited Financial
Statements in excess of $16,000, exclusive of any fees related solely to
material unusual items discovered during the course of such audit.
Notwithstanding anything to the contrary in this Section 10.7,
Company
shall be solely responsible for any all such fees and expenses incurred in
the
event that the Buyer terminates this Agreement prior to the Closing because
of
Company’s material breach of this Agreement or terminates the Agreement pursuant
to Section 8.1.5.
51
10.8 Attorneys’
Fees.
Should
suit be brought to enforce or interpret any part of this Agreement, the
prevailing party will be entitled to recover, as an element of the costs of
suit
and not as damages, reasonable attorneys’ fees to be fixed by the court
(including without limitation, costs, expenses and fees on any
appeal).
10.9 Notices.
Any
notice or other communication required or permitted to be given under this
Agreement will be in writing, will be delivered personally or by registered
or
certified mail, postage prepaid and will be deemed given upon delivery, if
delivered personally, or three days after deposit in the mails, if mailed,
to
the following addresses:
(a)
If
to
Buyer or Buyer Sub:
Neuro-Hitech,
Inc.
Xxx
Xxxx
Xxxxx, Xxxxx 0000
Xxx
Xxxx,
XX 00000
Attention:
President
with
a
copy to:
Arent
Fox
PLLC
0000
Xxxxxxxxxxx Xxxxxx, XX
Xxxxxxxxxx,
XX 00000
Attn:
Xxxxxxx X. Xxxxxx, Esq.
(b)
If
to
Company:
Q-RNA,
Inc.
0000
Xxxxxxxx, Xxxxx 000
Xxx
Xxxx,
XX 00000
Attention:
Chief Executive Officer
with
a
copy to:
Xxxxx
Xxxxxx LLP
000
Xxxxxxxx Xxxxxx, Xxxxx 000
Xxxxxx,
XX 00000
Attn:
Xxxxxx X. Xxxxxx and Xxxxx X. Xxxxxxx
or
to
such other address as a party may have furnished to the other parties in writing
pursuant to this Section 10.9.
52
10.10 Construction
of Agreement.
This
Agreement has been negotiated by the respective parties hereto and their
attorneys and the language hereof will not be construed for or against either
party. A reference to a Section or an exhibit will mean a Section in, or exhibit
to, this Agreement unless otherwise explicitly set forth. The titles and
headings herein are for reference purposes only and will not in any manner
limit
the construction of this Agreement which will be considered as a
whole.
10.11 Further
Assurances.
Each
party agrees to cooperate fully with the other parties and to execute such
further instruments, documents and agreements and to give such further written
assurances as may be reasonably requested by any other party to evidence and
reflect the transactions described herein and contemplated hereby and to carry
into effect the intents and purposes of this Agreement.
10.12 Absence
of Third Party Beneficiary Rights.
No
provisions of this Agreement are intended, nor will be interpreted, to provide
or create any third party beneficiary rights or any other rights or remedies
of
any kind in any client, customer, affiliate, stockholder, partner or any party
hereto or any other person or entity unless specifically provided otherwise
herein, and, except as so provided, all provisions hereof will be personal
solely between the parties that are signatories to this Agreement.
10.13 Public
Announcement.
Upon
execution of this Agreement Buyer and Company will issue a press release
approved by both parties announcing the Merger. Thereafter, Buyer may issue
such
press releases, and make such other disclosures regarding the Merger, as it
determines are required under applicable securities laws or regulatory
rules.
10.14 Confidentiality.
Company
and Buyer each recognize that they have received and will receive confidential
information concerning the other during the course of the Merger negotiations
and preparations. Accordingly, Buyer and Company each agrees (a) to use its
respective best efforts to prevent the unauthorized disclosure of any
confidential information concerning the other that was or is disclosed during
the course of such negotiations and preparations, and is clearly designated
in
writing as confidential at the time of disclosure, and (b) to not make use
of or
permit to be used any such confidential information other than for the purpose
of effectuating the Merger and related transactions. The obligations of this
section will not apply to information that (i) is or becomes part of the public
domain, (ii) is disclosed by the disclosing party to third parties without
restrictions on disclosure, (iii) is received by the receiving party from a
third party without breach of a nondisclosure obligation to the other party
or
(iv) is required to be disclosed by law. If this Agreement is terminated, all
copies of documents containing confidential information shall be returned by
the
receiving party to the disclosing party.
10.15 Entire
Agreement.
This
Agreement and the exhibits hereto constitute the entire understanding and
agreement of the parties hereto with respect to the subject matter hereof and
supersede all prior and contemporaneous agreements or understandings,
inducements or conditions, express or implied, written or oral, between the
parties with respect hereto. The express terms hereof control and supersede
any
course of performance or usage of the trade inconsistent with any of the terms
hereof.
[Signature
Page Next]
53
IN
WITNESS WHEREOF,
the
parties hereto have executed this Agreement as of the date first above
written.
BUYER:
|
COMPANY:
|
||
NEURO-HITECH,
INC.
|
Q-RNA,
INC.
|
||
By:
/s/
Xxxxx Xxxxxxx
|
By:
/s/
L. Xxxxxxx XxXxxxxx
|
||
|
|
||
Its:
Chief
Financial Officer
|
Its
Chief
Exeuctive Officer
|
BUYER
SUB:
|
REPRESENTATIVE:
|
||
QA
ACQUISITION CORP.
|
|
||
By:
/s/
Xxxxx Xxxxxxx
|
/s/
Xxxxx Xxxxxxxx
|
||
|
Xx.
Xxxxx Xxxxxxxx
|
||
Its:
Chief
Financial Officer
|
QA
MERGER LLC
|
|
||
By:
/s/
Xxxxx Xxxxxxx
|
|
||
|
|
||
Its:
Chief
Financial Officer
|
[SIGNATURE
PAGE TO AGREEMENT AND PLAN OF MERGER]
54
EXHIBIT
G
Deemed
value of one share of Buyer Common Stock: $6.00.
Deemed
value of one $13 Warrant: $4.56.
Deemed
value of one $18 Warrant: $4.11.
55